Podcasts about national cancer institute nci

Send us a textDr. Samir Khleif, MD is CEO of Georgiamune ( https://www.georgiamune.com/team ), a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases.  Dr. Khleif is a pioneer in the field of immunotherapy. He is a medical oncologist, immunologist, innovator, and entrepreneur, as well as a transformational executive in health care and biomedical research.Prior to becoming CEO of Georgiamune, Dr. Khleif served in different academic and leadership positions. He was a National Cancer Institute (NCI)/National Institutes of Health (NIH) scientist and Chief of the NCI Cancer Vaccine Section, where he led the development of pioneering immune-oncology and cancer vaccines into clinical trials. As a national and international academic leader, and detailed by the US government, he served as the founding director and CEO of the King Hussein Cancer Center ( https://www.khcc.jo/en ) in Amman, Jordan, where he led the development of the largest cancer center in the MENA region. He also served as the director of the Georgia Cancer Center, the state cancer center, at Augusta University. He is currently a biomedical scholar and holds a professorship at Georgetown University Medical School.Dr. Khleif also served as a Special Assistant to the Commissioner of the FDA, leading the FDA's Critical Path Initiative for Oncology. He is a member of the board of directors of Ayala Pharmaceuticals and Emerald Biopharmaceutics, and served as a member of the scientific advisory board of more than 20 biotechnology and pharmaceutical companies.Dr. Khleif is an international KOL in immunology and immunotherapy. He has served on many national committees, including the Scientific Advisory Board of the Biden Cancer Initiative, as chair of the Immunotherapy Committee for NRG, and as a member of the NCI Cooperative Group. He currently serves as an advisor for the Parker Institute for Cancer Immunotherapy. Dr. Khleif is an editor of three books, the author of hundreds of peer-reviewed scientific research articles, and a prolific inventor with more than 150 patents issued or pending in the field of immunology and immunotherapy.Dr. Khleif received his medical degree at the University of Jordan, Amman Jordan. He completed his residency in Internal Medicine at the Medical College of Ohio and his fellowship in Medical Oncology at the National Cancer Institute (NCI) in Bethesda, Maryland.#SamirKhleif #Georgiamune #Immunotherapy #KingHusseinCancerCenter #CriticalPathInitiative #FDA #Tregs #RegulatoryTCells #Cancer #Oncology #CheckpointInhibitors #ImmuneEscapeMechanisms #DualFunctioningAntibody #Autoimmune #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

A recently published study by the National Cancer Institute (NCI) discovers a link between physical activity and cancer risk after gathering data from wrist sensors, which could help lead to major advances in cancer research. Alaina Shreves, predoctoral fellow at NCI's Division of Cancer Epidemiology and Genetics Metabolic Epidemiology Branch, said the findings come from accelerometer-measured physical activity, which associated low-intensity exercise with up to a 26 percent decreased risk of certain cancers. Shreves highlighted the importance of wrist sensor data in cancer prevention. She also shared her excitement about a new project involving wearable technologies to determine how walking patterns impact cancer development.

Margaux Stack-Babich, Community Outreach and Engagement Manager for UC San Diego Moores Cancer Center,discusses the Center's prestigious National Cancer Institute (NCI) designation; the cancer burden in San Diego County; its Cancer Health Equity Collaborative; and its podcast project, The Science Of.About Spotlight and Cloudcast Media "Spotlight On The Community" is the longest running community podcast in the country, continuously hosted by Drew Schlosberg for 19 years.  "Spotlight" is part of Cloudcast Media's line-up of powerful local podcasts, telling the stories, highlighting the people, and celebrating the gravitational power of local.  For more information on Cloudcast and its shows and cities served, please visit www.cloudcastmedia.us. Cloudcast Media | the national leader in local podcasting.   About Mission Fed Credit Union A community champion for over 60 years, Mission Fed Credit Union with over $6 billion in member assets, is the Sponsor of Spotlight On The Community, helping to curate connectivity, collaboration, and catalytic conversations.  For more information on the many services for San Diego residents, be sure to visit them at https://www.missionfed.com/

The National Cancer Institute (NCI) is exploring how it can leverage artificial intelligence to enhance cancer screening techniques, ultimately improving patient outcomes across the nation. Dr. Katrina Goddard, director of the Division of Cancer Control and Population Sciences at NCI, explains how her division is leveraging AI, and other innovative solutions like the low-dose CT scan, to better detect lung cancer and enable better access to data.

In this episode of the Bench to Bedside Podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, discusses exciting advancements in the treatment of acute myeloid leukemia (AML) with Dr. Tara Lin, director of the adult leukemia program at KU Cancer Center and site principal investigator for myeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice), a precision-medicine initiative sponsored by the National Cancer Institute (NCI). MyeloMATCH is an “umbrella trial,” a group of clinical substudies for people with acute myeloid leukemia or myelodysplastic syndrome. In this conversation Dr. Lin explains the challenges of AML, as well as the innovative aspects of the myeloMATCH trial, such as rapid diagnostic testing and specialized clinical trial options based on genetic and molecular features. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about the myeloMATCH trial View the myleoMATCH trial on the NCI's clinical trials database Learn more about AML Read about clinical trials at KU Cancer Center Learn more about Dr. Tara Lin

Cutting-edge technology is transforming health care, with solutions like artificial intelligence helping agencies like the National Cancer Institute (NCI) improve screening, diagnosis and treatment. During AWS re:Invent in Las Vegas, Nevada, NCI CIO Jeff Shilling discussed the critical role of data standardization backing AI initiatives and how he is thinking about ethical concerns like bias, data privacy and risk management to ensure AI is both effective and responsible. He highlighted the importance of regulating AI in the medical field and how its future might require practices like data certification. Tune in to learn how the agency is working to overcome challenges related to data management and security while staying aligned with organizational priorities.

Breast cancer is the second most common cancer in women behind skin cancer, with approximately 13.1% of women estimated to receive a diagnosis of breast cancer at some point in their lifetime. The National Cancer Institute (NCI) is pioneering research to understand how we can better prevent breast cancer and promote risk reduction. In honor of Breast Cancer Awareness Month, NCI Division of Cancer Prevention Breast and Gynecological Cancer Research Chief Dr. Brandy Heckman-Stoddard about cutting-edge solutions in cancer prevention and how you can talk to your family and doctors to stay ahead in protecting your health. Dr. Brandy Heckman-Stoddard has led the Breast and Gynecological Cancer Research Group in NCI's Division of Cancer Prevention for 6 years. She is also currently the acting chief of the division's community oncology and prevention trials and is the project scientist for breast cancer and uterine cancer for the Cancer Intervention and Surveillance Modeling Network. She has been with NCI since serving as a cancer prevention fellow in 2009. More Links and Information Check out more Fors Marsh Media Connect or partner with Fors Marsh Explore NCI's Breast Cancer Risk Assessment Tool Learn more about breast cancer on NCI's website Learn about mammograms and recommendations for screening Explore oncological clinical trials on ClinicalTrials.gov, NCORP, and NCI's other programs. 

This time on the Anatomy in Clay® Learning System podcast, a chat with Dr. Amit Kumar and four students from Urbana STEMM in Urbana, Maryland. The four students are all ninth-graders - Rhea Ramesh, Aarna Chakavarty, Ritika Rajesh, and Hamsini Chintala.   In his professional life, Dr. Kumar is a Health Science Administrator at the National Cancer Institute (NCI), National Institutes of Health. He started at NIH as a post-doctoal fellow and has stayed at NIH since 1998, leading to his current position.  Dr. Kumar enjoys volunteering his time for the community.  Dr. Kumar has been engaging students (Elementary, Middle and High schools) in many educational and community activities through his non profit organization Urbana STEMM. (The second ‘M' stands for Mindfulness.) The program recruits and trains high schoolers who then go on to teach math, robotics, human anatomy and other STEMM related activities.  Many of his volunteers have earned awards including the presidential service award from AmeriCorp and awards from Point of Light and Frederick County government and education boards. The students in the program also engage in lot of community activities and programs such as community gardens, community road and park and nature wood cleaning, food and book drives, battery recycling to name a few,  Dr. Kumar is  also the Maryland coordinator of  Recycle My Battery organization,  which has about 60 student members in Frederick. Through their efforts, they have recycled about 30,000 batteries in Frederick and educated thousands of residents.  Dr. Kumar also volunteers with  local and national organizations such as Asian American Center of Frederick, Ekal Foundation and Northsouth Foundation that generate funds from their social and educational activities in the US to help underprivileged kids in tribal and poor villages of India.   More about Urbana STEMM:   Intro and Outro music "Vicious Pen" courtesy of Moby Gratis  

We go to the gym, watch what we eat, many of us use condoms for safer sex experiences, yet one area we don't concern ourselves with  - so to speak is our butt health. Sure we know about prostate cancer and the such, but when was the last time you ask your Doctor about the health of your butt. Starting today, we make butt health a priority - and it has nothing to do with having sex with men. It actually has everything to do with a better understanding of how and what butt (anal) cancer is and how it starts, and what you can do to prevent it. Dr. Gary Bucher a leader in clinical care for all things anal and perianal precancerm talks candidly about what you should be doing to prevent cancer in your bum. In this episode we discuss: The high risk groups for anal cancer Practices you should implement to ensure you butt stays healthy The three leading screenings every man and woman should have to catch anal cancer early Bottoms up boys and let's talk about our butts! About Dr. Gary Bucher For over 35 years, Dr. Bucher has been a leader in clinical care and research with HIV/ AIDS patients. He has felt the need to be on the forefront of advances and care for PLWH. Dr. Bucher saw the rates of anal cancer increasing in PLWH, MSM and other high-risk groups. Dr. Bucher started referring patients for work up for abnormal anal pap smears (anal cytology) to colorectal surgeons. He soon found out that his patients were not getting the appropriate evaluation with high resolution anoscopy (HRA). His patients were examined with a rectal exam and a standard plain anoscopy. Subsequently, they were told that everything was normal when they could have had anal precancer that was not seen because an HRA was not performed. His patients felt a false sense of security that they were being evaluated properly and that all was normal. Dr. Bucher quickly found that evaluation and treatment of anal and perianal precancer were nonexistent in Chicago and decided he needed to learn how to perform HRA's and treat anal precancer. In 2008, Dr. Bucher was so concerned about the trajectory of anal disease in his community, that he started focusing exclusively on providing HRA and HPV related anal disease treatments and opened his Anal Dysplaisa Clinic MidWest (ADC MidWest) in Chicago. Dr. Bucher's experience continued to evolve with his clinical practice and research to the point where he was able to participate as the principal investigator in the largest anal cancer prevention study (ANCHOR Study) ever conducted in the USA. Dr. Bucher's private clinical practice enrolled 580 participants from the Chicagoland region out of the 4,446 total U.S. participants. The ANCHOR Study is an anal cancer prevention clinical trial funded by the National Institutes of Health (NIH) through the National Cancer Institute (NCI) and it's Office of HIV and AIDS Malignancy (OHAM) and AIDS Malignancy Consortium (AMC). Dr. Bucher has remained passionate about the the clinical advancements in the treatment of HPV related diseases. In 2020, Dr. Bucher began to develop a mentorship training program to prepare the next generation of providers in anal precancer screening and treatment. The multi-tiered preceptorship program officially launched in 2023 and is primed to fill a much needed gap in the growing need for providers who are proficient in HRA and HSIL treatments. Connect With Dr. Bucher Website Instagram Hey Guys, Check This Out! Are you a guy who keeps struggling to do that thing? You know the thing you keep telling yourself and others you're going to do, but never do? Then it's time to get real and figure out why. Join the 40 Plus: Gay Men Gay Talk, monthly chats. They happen the third Monday of each month at 5:00 pm...

Melody of Miriam: https://open.spotify.com/track/48ZamQlV3BYQ0Y2V3nVQsq?si=KPviRnejR8eJWuvPQYctdA&context=spotify%3Aalbum%3A5rcHF9LH4YGyXzkJXnbnoj   This episode features Dr. Daniel Edelman sharing his journey from a traditional Jewish upbringing to pursuing a career in science, despite initial aspirations for a Kollel life. They discuss challenges faced by Orthodox Jewish women in secular fields and initiatives to integrate them into science careers. Dr. Edelman talkes about a mentorship program he founded addressing cultural clashes and the importance of maintaining personal values. The program's impact is evident through participant achievements, culminating in presentations at NIH poster day. Over 60 women have benefited, underscoring the importance of mentorship and community support for Orthodox Jewish women in science. The discussion also raises questions about gender-specific mentorship needs within the community.   About Our Guest: Daniel Edelman, PhD, initially wanted to be a Rebbe in a Yeshiva Gedolah. However, Rabbi Yaakov Weinberg, ZT”L, suggested Plan B; as in B in Biology! Dr. Edelman earned his M.S. in Applied Molecular Biology at the University of Maryland, Baltimore County in 1993. He then worked as a research associate at the VA Medical Center in Baltimore and as a molecular technologist at the University of MD Medical Center in Baltimore. In 1997, Dr. Edelman began dissertation research in infectious disease and earned his PhD in medical pathology in 2005. From 2006-2007, he worked as a scientific reviewer with the Food and Drug Administration (FDA). Next up was 13 years at the National Cancer Institute (NCI) as the laboratory manager of the Clinical Molecular Profiling Core supporting NCI clinical cancer research. While there he also began a program to provide a mentored pathway into the sciences for Orthodox Jewish women. From 2020-2023, Dr. Edelman returned to the FDA as a policy analyst. Now back at NCI since last fall, he now works as a program officer focusing on cancer screening and clinical trials. All statements by Dr. Edelman are his alone and do not reflect those of the US Government.   Would you like to be a SPONSOR? Would you like to join the Whatsapp Discussion Group? Reach out about new sponsorship opportunities for your brand & organizations - franciskakay@gmail.com Check out www.JewishCoffeeHouse.com for more Jewish Podcasts on our network.

Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women's cancers. We're excited to welcome Sean back to the podcast – he last appeared on episode 130 in late 2022. Sean provides an update on all the exciting things that have happened at Olema since then, including an update on their lead product candidate. Sean reflects on navigating the challenging biotech market environment over the past year, making careful spending decisions, and raising significant capital to extend Olema's runway. He also offers advice to first-time CEOs on building a strong support network to guide company growth. Biography: Dr. Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. He is also a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.

What are the latest advancements in cancer research and innovation? Join us in this episode of BioTalk with Rich Bendis as we explore the dynamic world of cancer research and technology development with our distinguished guest, Michael Weingarten, Director of the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI). Mr. Weingarten plays a pivotal role in leading a team of Program Directors managing the NCI's SBIR & STTR Programs, overseeing a substantial portfolio of $182 million in grants and contracts annually. These programs are at the forefront of NCI's efforts to drive innovation, fostering the development and commercialization of groundbreaking technologies and products for cancer prevention, diagnosis, and treatment. Explore the intersection of the BioHealth Capital Region and the NCI, understanding how collaboration and partnerships are shaping the future of cancer research and innovation. Finally, we delve into the goals for the future, highlighting the NCI's vision and commitment to advancing cancer prevention, diagnosis, and treatment through technology and innovation.

Epidemiologists are the watchful guardians of public health. They collect and analyze data to track the status quo. When there are deviations, they crunch the numbers to understand who is getting sick, where, how, and why. Dr. Meredith Shiels is an epidemiologist and senior investigator at the National Cancer Institute (NCI) studying cancer mortality rates to discern what populations might be at higher risk, figure out ways to mitigate those risks, and evaluate whether those measures are working.   Learn more about Dr. Shiels's research at  https://irp.nih.gov/pi/meredith-shiels.

In oncology, the National Cancer Institute (NCI) is synonymous with the highest standard of cancer research in the U.S. Nearly 50 years ago, Massey Cancer Center first became an NCI-designated cancer center in 1975 and has maintained this status every five years – when the NCI evaluates Massey for its transdisciplinary research and approaches to cancer prevention and treatment. This year, the NCI declared Massey a Comprehensive Cancer Center, its highest level of recognition. In this episode, Dr. Robert A. Winn, director of the VCU Massey Cancer Center and senior associate dean for cancer innovation and professor of pulmonary disease and critical care medicine at the VCU School of Medicine, discusses Massey's latest NCI achievement, and explains the impact this accolade will have on the cancer center and its community. An NCI-designation is not just an award. It comes with an array of opportunities for cancer centers to deepen their research, recruit top-tier scientists and advance pathways for new cancer treatments.

In this week's episode of "Pushing the Limits" I interview the incredible Dr Ross Pelton AKA the Natural Pharmacist. Ross Pelton is a pharmacist, nutritionist, author and a health educator who is widely recognized as the world's leading authority on drug-induced nutrient depletions. He was named one of the top 50 most influential pharmacists in the United States by American Druggist magazine for his work in Natural Medicine. He is the author of 13 books including his latest one which we do a deep dive into today on Rapamycin and longevity science  About the Book and what you will learn about in this episode (Disclaimer: none of this is medical advice, it is for educational purposes only)  Rapamycin, mTOR, Autophagy and Treating mTOR Syndrome We discuss how the prescription drug rapamycin can increase longevity. After the discovery of rapamycin, scientists began conducting experiments in an effort to understand rapamycin's mechanism of action. This led to the discovery of mTOR, which in turn, led to the understanding of how mTOR and autophagy regulate cellular metabolism and ultimately, the health and life of all living things. The discovery of rapamycin resulted in scientific studies that have enabled scientists to gain a totally new understanding of the aging process and how we might use this new information. The topics in this book are collectively one of the most important breakthroughs in the science of life extension that has ever been discovered. Discovery of Rapamycin: Strain of bacteria named Streptomyces hygroscopicus Discovered from a soil sample taken from Easter Island Exhibited anti-proliferative properties   The bacterium was discovered from a soil sample taken during a scientific expedition to Easter Island in 1964. The purpose of that expedition was to search for new compounds that might express antifungal and/or antibiotic properties. Rapamycin expressed strong antifungal activity. However, efforts to develop rapamycin as an antifungal drug were discontinued when it was discovered to have potent immunosuppressive activity. Rapamycin also exhibited anti-proliferative properties, which prompted scientists to send samples of rapamycin to the National Cancer Institute (NCI). Tests conducted there revealed two remarkable findings. The first revelation was that rapamycin suppressed the growth in a variety of solid tumors. Rapamycin's Mechanism of Action Over the past 25 years, research into rapamycin's mechanism of action has resulted in the discovery of a new understanding of cellular biology and the aging process. This research has revealed that two mechanisms named mTOR and autophagy, which are found inside every cell, are critical regulators of cellular metabolism. Breakthrough: Rapamycin's Use in Humans A groundbreaking study titled mTOR inhibition improves immune function in the elderly was published that ushered in the era of rapamycin use in humans. The study was conducted by Joan Mannick, MD, who was a senior scientist at Novartis. In addition to being a human clinical trial, Mannick's study is important because it sheds light on WHY and HOW rapamycin can be used safely and effectively in humans to slow down the onset of age-related diseases and increase lifespan and healthspan. We also discuss drug induced nutrient depletions. You can find Dr Ross at:  https://www.naturalpharmacist.net/ Also check out the Anti-aging range of supplements and information at https://theantiaging.store You can get Dr Peltons book here:   If you are wanting to Lactobacillus Fermenteum ME-3 from Dr Ohhira you can now get this in our shop here:   For the professional grade Probiotic from Dr Ohhira that is fermented for 5 years, also mentioned in this podcast you can get that here:   Health Optimisation and Life Coaching with Lisa Tamati Lisa offers solution focused coaching sessions to help you find the right answers to your challenges. Topics Lisa can help with:  Lisa is a Genetics Practitioner, Health Optimisation Coach, High Performance and Mindset Coach. She is a qualified Ph360 Epigenetics coach and a clinician with The DNA Company and has done years of research into brain rehabilitation, neurodegenerative diseases and biohacking. She has extensive knowledge on such therapies as hyperbaric oxygen,  intravenous vitamin C, sports performance, functional genomics, Thyroid, Hormones, Cancer and much more. Testing Options Comprehensive Thyroid testing DUTCH Hormone testing Adrenal Testing Organic Acid Testing Microbiome Testing Cell Blueprint Testing Epigenetics Testing DNA testing Basic Blood Test analysis She can help you navigate the confusing world of health and medicine and can advocate for you. She can also advise on the latest research and where to get help if mainstream medicine hasn't got the answers you are searching for whether you are facing challenges from cancer to gut issues, from depression and anxiety, weight loss issues, from head injuries to burn out.: Consult with Lisa    Join our Patron program and support the show Pushing the Limits' has been free to air for over 8 years. Providing leading edge information to anyone who needs it. But we need help on our mission.  Please join our patron community and get exclusive member benefits (more to roll out later this year) and support this educational platform for the price of a coffee or two You can join by going to  Lisa's Patron Community   Lisa's Anti-Aging and Longevity Supplements  Lisa has spent years curating a very specialised range of exclusive longevity, health optimising supplements from leading scientists, researchers and companies all around the world.  This is an unprecedented collection. The stuff Lisa wanted for her mum but couldn't get in NZ. Check out the range at her LongLifeLabs shop   Subscribe to our popular Youtube channel  with over 600 videos, millions of views, a number of full length documentaries, and much more. You don't want to miss out on all the great content on our Lisa's youtube channel. Youtube   Order Lisa's Books My latest book Relentless chronicles the inspiring journey of how my mother and I defied the odds after an aneurysm left my mum, Isobel, with massive brain damage at age 74. The medical professionals told me there was absolutely no hope of any quality of life again. Still, I used every mindset tool, years of research and incredible tenacity to prove them wrong and bring my mother back to full health within three years. Get your copy here: Lisa's Books   Our NMN Bio Flagship Longevity Range A range by molecular biologist Dr Elena Seranova NMN: Nicotinamide Mononucleotide, an NAD+ precursor Researchers have found that Nicotinamide Adenine Dinucleotide or NAD+, a master regulator of metabolism and a molecule essential for the functionality of all human cells, decreases dramatically over time.   What is NMN? NMN Bio offers a cutting edge Vitamin B3 derivative named NMN (beta Nicotinamide Mononucleotide) that can boost the levels of NAD+ in muscle tissue and liver. Take charge of your energy levels, focus, metabolism and overall health so you can live a happy, fulfilling life. Founded by scientists, NMN Bio offers supplements of the highest purity and rigorously tested by an independent, third-party lab. Start your cellular rejuvenation journey today.   Support Your Healthy Aging We offer powerful third-party tested NAD+ boosting supplements so you can start your healthy ageing journey today. Shop now: NMNBIO NMN (beta Nicotinamide Mononucleotide) 250mg | 30 capsules NMN (beta Nicotinamide Mononucleotide) 500mg | 30 capsules 6 Bottles | NMN (beta Nicotinamide Mononucleotide) 250mg | 30 Capsules 6 Bottles | NMN (beta Nicotinamide Mononucleotide) 500mg | 30 Capsules Boost Your NAD+ Levels — Healthy Ageing: Redefined Cellular Health Energy & Focus Bone Density Skin Elasticity DNA Repair Cardiovascular Health Brain Health Metabolic Health Listen to the episodes with Dr Seranova on the show: https://www.lisatamati.com/podcast--dr-elena-seranova/ https://www.lisatamati.com/podcast--dr-elena-seranova-part-3/   Perfect Amino Supplement by Dr David Minkoff Introducing PerfectAmino PerfectAmino is an amino acid supplement that is 99% utilised by the body to make protein. PerfectAmino is 3-6x the protein of other sources with almost no calories. 100% vegan and non-GMO. The coated PerfectAmino tablets are a slightly different shape and have a natural, non-GMO, certified organic vegan coating on them so they will glide down your throat easily. Fully absorbed within 20-30 minutes! No other form of protein comes close to PerfectAminos Listen to the episode with Dr MInkoff here:  Ketone Products by HVMN The world's best  exogenous Ketone IQ Listen to the episode with Dr Latt Mansor Lisa's  ‘Fierce' Sports Jewellery Collection For Lisa's gorgeous and inspiring sports jewellery collection, 'Fierce', go to Jewellery   For Vielight Device Vielight brain photobiomodulation devices combine electrical engineering and neuroscience. To find out more about photobiomodulation, current studies underway and already completed and for the devices mentioned in this video go to www.vielight.com Use code "tamati" at checkout to get a 10% discount on any of their devices.   Enjoyed This Podcast? If you did, subscribe and share it with your friends! If you enjoyed tuning in, then leave us a review and share this with your family and friends. Have any questions? You can contact my team through email (support@lisatamati.com) or find me on Facebook, Twitter, Instagram and YouTube. For more episode updates, visit my website. You may also tune in on Apple Podcasts. To pushing the limits, Lisa and team

The Osteosarcoma Institute (OSI) is currently supporting two clinical trials and seven laboratory research projects for osteosarcoma. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chand Khanna, DVM, PhD, Chair of the OSI's Strategic Advisory Board. Dr. Helman and Dr. Khanna will provide an overview of the OSI's osteosarcoma research portfolio and explain how the OSI identifies promising osteosarcoma research projects. Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute. Chand Khanna, DVM, PhD is Chief Science Officer with Ethos Veterinary Health, and President of Ethos Discovery(501c3), its incubator of scientific innovation. His responsibility at Ethos Discovery is to develop innovations in the form of novel diagnostics and therapeutics for both human and animal patients afflicted with similar complex disease conditions (i.e., osteosarcoma; so called Comparative Oncology). Dr. Khanna is a veterinary oncologist and both osteosarcoma and metastasis biologist, who has worked in this scientific field for over 20 years, most notably as a senior investigator of the Tumor and Metastasis Biology section of the Pediatric Oncology Branch at the National Cancer Institute and founding Director of its Comparative Oncology Program. Dr. Khanna's research career has focused on improving the understanding of the biology of metastasis in osteosarcoma and the use of a cross species (mouse, dog, human), Comparative and translational approach to develop novel therapeutics for osteosarcoma metastasis. He serves as the Chair of the Osteosarcoma Institute's Strategic Advisory Board. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

OSI Connect is the Osteosarcoma Institute's free, easy-to-use resource for patients who have been diagnosed with osteosarcoma or suffered a relapse after initial treatment. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chelsey Blanks, OSI Connect Administrator. You will learn how OSI Connect works and examples of how the program has helped more than 70 patients since its launch in 2019. Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute. As the Osteosarcoma Institute Operations Manager, Chelsey Blanks schedules meetings for the board, oversees various operational aspects of the organization (including HR, IT, and office management), facilitates the grant cycle, and manages OSI Connect (formerly OSI Hotline) that offers free expert advice for osteosarcoma patients and families no matter where they are in their journey. Although Chelsey is Texan through and through, she spent six years living in Southern California and was thrilled to return to the homeland with her husband, Jordan, at the end of 2019. Chelsey obtained her undergraduate degree from the University of North Texas, where she studied Sociology, Philosophy, and Dance. Previously, she had an insurance and financial services career and was an Executive Assistant for her church in Orange County, California. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

About 90% of nonmelanoma skin cancers are associated with ultraviolet radiation exposure. Sometimes prevention is straight forward: wear sunblock, stay shaded. But still, there are 1 million skin cancer diagnoses in the U.S. every year. Ultraviolet dosimeters are one of several technologies that are showing a lot of promise when it comes to preventing skin cancer. The tools collect personalized data about UV exposure and are linked to an app that allows people to enter information about their sun-protective behaviors like wearing sunscreen.  Psychologist Frank Perna, program director at the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences, Behavioral Research Program, and Health Behaviors Research Branch, discusses how programs like the Surveillance, Epidemiology and End Results (SEER) Program and the Classification of Laws Associated with School Students (CLASS) are helpful in tracking melanoma as well as capturing data about state policies related to sun safety and sunscreen use in schools.

According to the National Cancer Institute (NCI), Triple Negative Breast Cancer affects 13 in every 100,000 femailes in the U.S. TNBC -Triple Negative Breast Cancer accounts for about 10-20% of all breast cancers.  Risk factors Various risk factors raise the likelihood of developing TNBC. These include: Race: Black and Latinx people are more likely to receive a TNBC diagnosis than white people.Age: TNBC is more likely to present in people below the age of 50 years.Weight: Obesity increases the risk of receiving a diagnosis of TNBC.Genetic mutations: The BRCA1 gene mutation puts someone at higher risk of TNBC. Triple-negative breast cancer: Facts and stats (medicalnewstoday.com Is There a Vaccine for Breast Cancer? – Cleveland Clinic Vaccine study for HER2-positive breast cancer moves forward - Mayo Clinic Biomedical Research: Observations on DOD's Management of Congressionally Directed Medical Research Programs | U.S. GAO  

There is a bidirectional relationship between cancer and aging. The risk of developing cancer increases as we age, and research shows that cancer and some cancer treatments can accelerate aging. However, earlier detection and targeted therapies are making a difference. Paige Green, chief of the Basic Biobehavioral and Psychological Science Branch, explains that other factors such as psychosocial wellbeing also play a role in the aging process. Green and her colleagues at the National Cancer Institute (NCI) are taking a holistic approach to studying cancer and aging to help survivors lead longer, healthier lives.

Synopsis: Sean Bohen is the President and CEO of Olema Oncology, a company dedicated to developing targeted therapies for women with breast cancer. An oncologist by training, Dr. Bohen has a background in big pharma, having worked at Genentech and AstraZeneca before joining Olema. He talks with host Rahul Chaturverdi about the differences between working for biotech and big pharma companies, the work his team is pursuing at Olema, the opportunities and challenges within the breast cancer landscape, the ups and downs of running a biotech company and managing a team with the current market dynamics, and the importance of partnerships and how they can strength companies. Biography: Dr. Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. He is also a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.

The use of telehealth has accelerated across the health care landscape, including in treating cancer. But this digital delivery model comes with pros and cons, and more research is needed to determine how to best integrate it. The National Cancer Institute (NCI)'s Robin Vanderpool, who leads health communication and informatics research, highlights the four Telehealth Research Centers of Excellence (TRACE) that aim to help understand and improve telehealth for cancer care delivery.

For more information, please visit www.hdgenetics.com Wes is a Certified Genetic Counselor (CGC) through the American Board of Genetic Counseling. He earned a Master of Science in Genetic Counseling from Johns Hopkins University in 2021. As part of this program, Wes was an Intramural Research Trainee for the National Human Genome Research Institute (NHGRI) and National Cancer Institute (NCI) at the National Institutes of Health (NIH).  His graduate thesis research was titled “COVID-19 Impact on Genetic Counseling for Huntington's Disease via Teleheath”. Prior to graduate studies, Wes worked as an undergraduate laboratory assistant for Dr. Jeff Carroll at Western Washington University, studying the neurobiology and behavior of mice modeling Huntington's disease. In 2018, Wes was selected for HDSA's Donald A King Research Fellowship and in 2019 earned a Bachelor of Science in Behavioral Neuroscience. Wes runs all of HD Genetics' counseling sessions and will be the main point of contact throughout the genetic testing and counseling experience. You can reach out to Wes anytime with questions: Wes@HDgenetics.com

First trial to prove a diet supplement can prevent hereditary cancer Newcastle University (UK), July 25, 2022 A trial in people with high hereditary risk of a wide range of cancers has shown a major preventive effect from resistant starch, found in a wide range of foods such as oats, breakfast cereal, cooked and cooled pasta or rice, peas and beans, and slightly green bananas. An international trial—known as CAPP2—involved almost 1000 patients with Lynch syndrome from around the world, and revealed that a regular dose of resistant starch, also known as fermentable fiber, taken for an average of two years, did not affect cancers in the bowel but did reduce cancers in other parts of the body by more than half. This effect was particularly pronounced for upper gastrointestinal cancers including esophageal, gastric, biliary tract, pancreatic and duodenum cancers. The astonishing effect was seen to last for 10 years after stopping taking the supplement. "We found that resistant starch reduces a range of cancers by over 60%. The effect was most obvious in the upper part of the gut," explained Professor John Mathers, professor of Human Nutrition at Newcastle University. "This is important as cancers of the upper GI tract are difficult to diagnose and often are not caught early on. "Resistant starch can be taken as a powder supplement and is found naturally in peas, beans, oats and other starchy foods. The dose used in the trial is equivalent to eating a daily banana; before they become too ripe and soft, the starch in bananas resists breakdown and reaches the bowel where it can change the type of bacteria that live there. "Resistant starch is a type of carbohydrate that isn't digested in your small intestine; instead it ferments in your large intestine, feeding beneficial gut bacteria—it acts, in effect, like dietary fiber in your digestive system. This type of starch has several health benefits and fewer calories than regular starch. We think that resistant starch may reduce cancer development by changing the bacterial metabolism of bile acids and to reduce those types of bile acids that can damage our DNA and eventually cause cancer. However, this needs further research."   New study finds lowest risk of death was among adults who exercised 150-600 minutes/week Harvard School of Public Health, July 25, 2022 An analysis of more than 100,000 participants over a 30-year follow-up period found that adults who perform two to four times the currently recommended amount of moderate or vigorous physical activity per week have a significantly reduced risk of mortality, according to new research published today in the American Heart Association's journal Circulation. The reduction was 21-23% for people who engaged in two to four times the recommended amount of vigorous physical activity, and 26-31% for people who engaged in two to four times the recommended amount of moderate physical activity each week. In 2018, the United States Department of Health and Human Services' Physical Activity Guidelines for Americans recommended that adults engage in at least 150-300 minutes/week of moderate physical activity or 75-150 minutes/week of vigorous physical activity, or an equivalent combination of both intensities.  The analysis also found: Participants who met the guidelines for vigorous physical activity had an observed 31% lower risk of CVD mortality and 15% lower risk of non-CVD mortality, for an overall 19% lower risk of death from all causes. Participants who met the guidelines for moderate physical activity had an observed 22-25% lower risk of CVD mortality and 19-20% lower risk of non-CVD mortality, for an overall 20-21% lower risk of death from all causes. Participants who performed two to four times above the recommended amount of long-term vigorous physical activity (150-300 min/week) had an observed 27-33% lower risk of CVD mortality and 19% non-CVD mortality, for an overall 21-23% lower risk of death from all causes. Participants who performed two to four times above the recommended amount of moderate physical activity (300-600 min/week) had an observed 28-38% lower risk of CVD mortality and 25-27% non-CVD mortality, for an overall 26-31% lower risk of mortality from all causes. In addition, no harmful cardiovascular health effects were found among the adults who reported engaging in more than four times the recommended minimum activity levels. Previous studies have found evidence that long-term, high-intensity, endurance exercise, such as marathons, triathlons and long-distance bicycle races, may increase the risk of adverse cardiovascular events, including myocardial fibrosis, coronary artery calcification, atrial fibrillation and sudden cardiac death.   Treating dementia with the healing waves of sound Ultrasound applied to the brain could help treat patients with dementia. Tohoku University (Japan), July 20, 2022 Ultrasound waves applied to the whole brain improve cognitive dysfunction in mice with conditions simulating vascular dementia and Alzheimer's disease. The research, conducted by scientists at Tohoku University in Japan, suggests that this type of therapy may also benefit humans. The team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects. "The LIPUS therapy is a non-invasive physiotherapy that could apply to high-risk elderly patients without the need for surgery or anaesthesia, and could be used repeatedly," says Shimokawa. The Tohoku University team found that cognitive impairment markedly improved in mice with conditions similar to vascular dementia and Alzheimer's disease when LIPUS was applied to the whole brain three times a day for 20 minutes each time.    Study: ADHD drugs do not improve cognition in healthy college students University of Rhode Island, July 19, 2022 Contrary to popular belief across college campuses, attention deficit hyperactivity disorder (ADHD) medications may fail to improve cognition in healthy students and actually can impair functioning, according to a study by researchers at the University of Rhode Island and Brown University. Study co-investigators Lisa Weyandt, professor of psychology and a faculty member with URI's George and Anne Ryan Institute for Neuroscience, and Tara White, assistant professor of research in behavioral and social sciences at Brown University, had anticipated different findings. "We hypothesized that Adderall would enhance cognition in the healthy students, but instead, the medication did not improve reading comprehension or fluency, and it impaired working memory," she said. "Not only are they not benefitting from it academically, but it could be negatively affecting their performance." This first-ever multisite pilot study of the impact of so-called "study drugs" on college students who do not have ADHD comes at a time when use of prescription stimulants such as Adderall, Ritalin and Vyvanse is common among young adults who believe the drugs will improve their academic performance.  Results of the study, published in the journal Pharmacy, show that the standard 30 mg dose of Adderall did improve attention and focus -- a typical result from a stimulant -- but that effect failed to translate to better performance on a battery of neurocognitive tasks that measured short-term memory, reading comprehension and fluency. Weyandt has a theory about why working memory would be adversely affected by the medication. Brain scan research shows that a person with ADHD often has less neural activity in the regions of the brain that control executive function -- working memory, attention, self-control. For people with ADHD, Adderall and similar medications increase activity in those regions and appear to normalize functioning. "If your brain is functioning normally in those regions, the medication is unlikely to have a positive effect on cognition and my actually impair cognition. In other words, you need to have a deficit to benefit from the medicine," Weyandt said.         Guanabana: the cancer killer big pharma doesn't want you to know about Northeastern University, July 16, 2022  Guanabana is known by a variety of names -- including soursop, cherimoya, custard apple, Brazilian paw paw and graviola. As far back as the 1970s, the National Cancer Institute (NCI) investigated the merits of guanabana, and discovered the stems and leaves of the tree were successful in destroying cancer cells. "Inexplicably, the results [of the NCI research] were published in an internal report and never released to the public. Since 1976, guanabana has proven to be an immensely potent cancer killer in 20 independent laboratory tests, but as of now, no double-blind clinical trials," reports Christopher Lane, Ph.D., in Psychology Today. Moreover, this study found that a compound derived from the leaves of guanabana was "selectively cytotoxic for the lung (A-549), colon (HT-29), and pancreatic (PACA-2) cell lines with potencies equal to or exceeding those of Adriamycin." And research in the Journal of Natural Products discovered that extracts of guanabana demonstrated pesticidal, antimalarial, antiviral and antimicrobial properties. Likewise, Memorial Sloan Kettering Cancer Center states that guanabana shows anti-inflammatory and anticancer effects in vitro and in vivo. Revered for centuries in South America and Southeast Asia, the bark, leaves, root, seeds and fruit have been used to tame heart disease, asthma, liver issues and arthritis. Guanabana is also helpful for treating sleep disorders, fevers and cough. According to the article, "Guanabana--Medicinal Uses?" extracts of the plant: Attack cancer safely and effectively with an all-natural therapy that does not cause extreme nausea, weight loss and hair loss. Protect the immune system. Boost energy and outlook on life. Effectively target and kill malignant cells in 12 types of cancer -- including colon, breast, prostate, lung and pancreatic cancer. Proved to be up to 10,000 times stronger in slowing the growth of cancer cells than Adriamycin, a commonly used chemotherapeutic drug. Selectively kill only cancer cells, unlike traditional chemotherapy treatments.  *A word of caution: Excessive consumption of guanabana can lead to neuronal dysfunction and degeneration with symptoms similar to Parkinson's disease. Consult with a qualified practitioner before taking guanabana on a daily basis.     High-strength cannabis linked to addiction and mental health problems University of Bath (UK), July 25, 2022 As the strength or potency of cannabis products has increased internationally over the years, so have rates of people being treated for cannabis addiction, say the authors of a new study. Researchers from the Addiction and Mental Health Group at the University of Bath (UK) have systematically analyzed the relationship between the types of cannabis people use and their addiction and mental health problems. Their work draws on 20 studies involving almost 120,000 people. The new study, published in The Lancet Psychiatry, suggests that people who use high-potency cannabis are more likely to experience addiction than those using low-potency products. It also suggests that people using high-potency cannabis are more likely to experience a psychotic disorder, such as schizophrenia. These findings may help to explain why more people have received treatment for cannabis problems over recent years. Data from the European Monitoring Centre for Drugs and Drug Addiction show a 76% increase in people entering treatment for cannabis addiction in the past decade.

The University of Kansas Cancer Center has been designated as a “comprehensive” cancer center by the National Cancer Institute (NCI). It's the highest level of recognition awarded by the NCI and is the gold standard for cancer centers. Our experts talk about what that means and about the impact this will have on cancer research and the future of cancer care.

Guest host Dr. Vamsi Velcheti, of the NYU Langone Perlmutter Cancer Center, and Dr. Brian Henick, of the Columbia University Herbert Irving Comprehensive Cancer Center, discuss advances in KRAS-mutated lung cancer in the KRYSTAL-1 trial, and the association of ctDNA with overall survival in the NADIM trial, as well as other key advances in lung cancer presented at the 2022 ASCO Annual Meeting.   TRANSCRIPT   Dr. Vamsi Velcheti: Hello, everyone! This is Dr. Vamsi Velcheti, I'm your guest host for the ASCO Daily News podcast, today. I'm an associate professor and medical director for the Thoracic Oncology Program at Perlmutter Cancer Center at NYU Langone Health. My guest today is Dr. Brian Henick, an associate director of the Experimental Therapeutics Program, and assistant professor of Medicine at Columbia University's Herbert Irving Comprehensive Cancer Center. We'll be discussing key abstracts in lung cancer that were featured at the 2022 ASCO Annual Meeting. Our full disclosures are available in the notes and disclosures of all guests on the podcast can be found on the transcripts at asco.org/podcasts. Brian, it's great to speak with you today. Dr. Brain Henick: Thank you so much, Vamsi, and ASCO Daily News for letting me join you to discuss these abstracts. Dr. Vamsi Velcheti: So, let's dive in. So, it's an exciting ASCO Annual Meeting. And I hope you had a great time at the Meeting. So, let's start off with the LBA9009 and KRYSTAL-1 clinical trial. The study showed the activity of adagrasib in patients with KRAS-G12C mutant non-small cell lung cancer and active untreated brain mets. So, what is the key takeaway from this trial? Dr. Brain Henick: Well, Dr. Sabari presented some encouraging data on this important population. As we know, patients with active central nervous system (CNS) metastases represent a population of unmet medical need who are often excluded from clinical trials. So, it's a credit to the investigators for including this cohort. As Dr. Sabari noted, and as Dr. Goldberg emphasized in her discussion of the abstract, the measured CNS penetration of adagrasib compares favorably with other CNS active compounds from other settings. The overall response rate was 35%, with a disease control rate of 80%. But impressively, the median duration of intracranial response and progression-free survival (PFS) wasn't reached. This certainly seems to be a CNS active compound, and we'll need to see how sotorasib stacks up in their comparable cohort. Ideally, we'd have randomized data to prove superiority over the standard of care, but we may be a few steps away from that. Dr. Vamsi Velcheti: So, Brian, in terms of CNS mets, how big of a problem is it in patients with KRAS G12C mutant lung cancers? Dr. Brian Henick: We know that CNS metastases are a big problem for G12C mutant lung cancer. The rates have been quoted as high as up to 42% of patients. And in particular, as you know, Vamsi, a lot of times trials often don't include, specifically, cohorts with active untreated brain metastases. And so, this is a very unique cohort in that sense. Dr. Vamsi Velcheti: I just want to highlight that we really don't know the differential efficacy of sotorasib and adagrasib in the CNS met population because the trials were CodeBreak 100 and other trials and data readouts from sotorasib did not include patients with untreated brain mets. We did, however, [see] CNS progression-free survival data that go in line with sotorasib. So, it's really important to see that data from sotorasib. Dr. Brain Henick: I definitely look forward to seeing that. Dr. Vamsi Velcheti: So, let's talk about Abstract 8501. The primary endpoint that was presented at ASCO [Annual Meeting] was the pathologic complete response to chemotherapy and nivo vs. chemotherapy as a new adjuvant treatment for resectable stage 3, a non-small cell lung cancer. This was the phase 2 NADIM trial. So, what do you think about this study? And what's your key takeaway from the study? Dr. Brain Henick: Dr. Provencio from Spain presented data from this randomized study as you said, of nivo plus carbo taxol compared to carbo taxol as neoadjuvant therapy for potentially resectable stage 3-A and B non-small cell lung cancer. So, I did want to compare this to the randomized data that we have from Checkmate 816, which interestingly allowed for earlier-stage disease as low as 1-B. And they also allowed for more flexibility in the choice of platinum doublet regimens. This study, NADIM 2, employs 2:1 versus 1:1 randomization, which we saw in Checkmate 816. Another important difference was that NADIM 2 required adjuvant nivolumab for 6 months in the study arm, whereas Checkmate 816 didn't include any immunotherapy in the adjuvant setting, but they allowed for a standard of care chemotherapy. In NADIM 2, the control arm didn't include any adjuvant therapy. In keeping with the impressive improvements over historical pathologic complete response rates of about 5%, this chemotherapy-IO regimen yielded a path complete response (CR) rate of 36.8%. It also showed a major pathological response, which again is defined as less than 10% viable tumor of 52.6%, and an overall response rate of 75.4%. So, it looks like there's a benefit that's happening upfront with the immunotherapy and chemotherapy as opposed to this just being an adjuvant phenomenon. This is also in keeping with data that we saw with Checkmate 816, as well as neoadjuvant atezo plus chemotherapy in the phase 2 study that was led by Catherine Shu and colleagues here at Columbia a few years ago. Overall, this is more encouraging data for the neoadjuvant use of immunotherapy. The earlier immunotherapy marches into the treatment course of patients with lung cancer, the greater the cost of toxicity. So, I think an important thing for us to focus on going forward is trying to develop strategies to better identify the patients that are most likely to benefit. Dr. Vamsi Velcheti: So, Brian, I think from a practical standpoint, now that we have approval for neoadjuvant immunotherapy and adjuvant immunotherapy, we have some practical challenges in terms of how we manage our patients. Of course, the new adjuvant is very appealing because it's only 3 cycles of chemoimmunotherapy, but the challenge though, is a majority of the patients don't have a CR, or a significant proportion of the patients have an ongoing response or significant residual disease at the time of surgery. So, the question then would be what do you do after surgery if they're having an ongoing response? Do you think 3 cycles of immunotherapy are inadequate systemic therapy for these patients? Dr. Brian Henick: It's a really important question, Vamsi. I think until the data is mature, we're just kind of limited by the extent of what the data tells us so far, and then we have to kind of do our best as the treating doctor to navigate the patient's situation. So, tools that we'd still have available to us in the adjuvant setting that are approved are things like chemotherapy and radiation, leveraging things like circulating tumor DNA, I think maybe a promising path forward, as well to help guide strategies there, but I think until the data is mature, it has to be highly patient-focused to figure out what seems to be most appropriate there. How are you navigating those situations, Vamsi? Dr. Vamsi Velcheti: Yeah, as you said, it is very challenging. I think we need more data. And of course, the challenge now is like, if you use immunotherapy in the new adjuvant setting, it's very likely you're not going to get insurance authorization for 1 year of adjuvant atezolizumab. So, we really need studies to optimize treatment paradigms here. As you suggested, maybe circulating tumor DNA (ctDNA)-based approaches to look at residual disease, I think, that would be one great way to do it. Let's move on to the next abstract, Brian. I found Abstract 9001 really interesting. It's a U.S. Food and Drug Administration (FDA) pooled analysis that looked at outcomes of first-line immune checkpoint inhibitors, with or without chemotherapy based on the KRAS mutation status and PD-L1 expression. So, what is your take on this abstract and how do you think this is going to impact our practice? Dr. Brian Henick: So, Dr. Nakajima and colleagues explored the observation from individual trials that patients with KRAS-mutant lung cancer seem to have better responses than wild type with immunotherapy (IO) alone. But the favorability of these responses seems to be abrogated with chemotherapy-IO. We know that KRAS accounts for 25% of oncogene-driven non-small cell lung cancer predominantly at amino acid 12. And with the emergence of direct inhibitors of G12C, understanding the clinical features of these tumors may be critical to inform optimal integration of this new class of drugs and also to make sure that we've optimized treatment algorithms for KRAS patients in general. So, this study's authors at the FDA pulled data from 12 registrational clinical trials that were investigating first-line checkpoint inhibitor-containing regimens and they found no significant difference between KRAS wild type and mutant for overall survival regardless of the regimen used. The best outcomes were seen with chemoimmunotherapy regardless of KRAS status. This retrospective analysis does suggest that the notion of there being lesser benefit from chemoimmunotherapy from Dr. Gadgeel's study might not hold up in the overall population, but I think it raises important questions, like, are all KRAS mutations alike? The absence of KRAS mutation status for a majority of patients included in these studies limits the interpretation of the data. And also, the absence of commutation status makes it a little harder to interpret. And other important questions remain such as how G12C inhibitors will factor in? What were your thoughts, Vamsi? Dr. Vamsi Velcheti: No, I completely agree with you, Brian. I think we need more data and we know that commutation status is a very important aspect in terms of KRAS-directed therapies. And of course, with a lot of promising data from these KRAS inhibitors, there's an interest in moving these drugs into the front-line therapy for patients with KRAS mutations. But I think it's going to be quite challenging to incorporate them into the front-line therapies and we clearly will need better characterization of these patients with KRAS mutant [lung cancer] to further personalize treatment in the frontline setting for these patients. So, let's move on to the next abstract. This is the lung map study, Abstract 9004. This is a study sponsored by the National Cancer Institute (NCI), the lung map study, looking at overall survival from a phase 2 randomized study of ramucirumab and pembrolizumab, what's the standard of care in patients with advanced non—small cell lung cancer previously treated with immunotherapy. So, what were your key takeaway points here from this study? Dr. Brian Henick: So first of all, it's very exciting to see data from this very ambitious long map sub-study yield a positive result. Whereas many of the arms of this study were biomarker-guided, Dr. Reckamp presented the results from pembro plus ramucirumab as compared to the standard of care in unmarked patients with non-small cell lung cancer who had progressed after prior treatment with chemotherapy and immunotherapy. The data seems to suggest that pembro plus ramucirumab may be better tolerated than the standard of care chemo-containing regimens, as the experimental regimen had fewer serious adverse events. Pembro plus ramucirumab had a median overall survival of 14.6 months as compared to 11.6 months in the control arm and this was statistically significant. The PFS difference wasn't significant, but there was a late divergence in the curves. Dr. Bestvina nicely summarized some of the study's limitations such as the mixture of control regimens used, and there were really interesting signals that were found on subgroup analysis, such as benefit in those with mixed histology tumors, STK11 mutant tumors, and those who received chemotherapy prior to immunotherapy. The subgroups deserve further attention in the future. For now, this regimen may be an appealing option as an alternative to chemotherapy for the right patients. What do you think? Dr. Vamsi Velcheti: Yeah, I agree, Brian. I think it's a really promising combination. We've always seen some synergy with VEGF inhibitors and immunotherapy in multiple studies and multiple tumor types. So, we really need to develop better ways to select patients for VEGF combination-based approaches in lung cancer. So, let's move on to another interesting study. This is Abstract 9000. This explores the outcomes of anti-PD-L1 therapy with or without chemotherapy for first-line, metastatic non-small cell lung cancer with a PD-L1 score of greater than 50%. So, this is an FDA pooled analysis. So, what were your key takeaways from this abstract? Dr. Brain Henick: I thought this question was really well suited for a large pooled retrospective analysis and our colleagues at the FDA didn't let us down here. The question really was what's the optimal approach for patients with non-small cell lung cancer with greater than 50% PD-L1 in view of the absence of direct comparisons between these arms in prospective studies? I thought one of the most striking findings from Dr. Akinboro's presentation was the dismally low rate of underrepresented minority patients that were included in these registration trials. As far as the findings for the patients who were studied, although the Kaplan-Meier curves for overall survival showed early separation, the difference wasn't statistically significant. Subgroup analysis revealed a trend towards better outcomes for immunotherapy alone among patients who are [age] 75 and above, suggesting that this may need to be parsed out as a unique population in subsequent studies. But in all, our equipoise as a field on whether to include chemoimmunotherapy-based first-line regimens should persist and should be guided, in my opinion, largely by clinical considerations. Can the patient tolerate chemotherapy? Do you need a rapid response? Are there other things that you thought in hearing all this, Vamsi? Dr. Vamsi Velcheti: Yeah, absolutely. I think I am still struggling with the decision of whether to add chemotherapy for patients with greater than 50%. To a large extent, it's actually a clinical decision. In some patients who have a large disease burden, I tend to kind of opt for adding chemotherapy to immunotherapy in the front-line setting. But of course, we need more data here. And this is actually a very helpful piece of information from the FDA. And as you pointed out briefly, Brian, I think the fact that there are very few underrepresented patients in the pooled analysis, I think kind of speaks to the need for addressing increased diversity in clinical trial accruals. I think this is a great segue to also talk about Abstract 9012, talking about disparities in access to immunotherapy globally. This is a study from India looking at 15,000 patients who were checkpoint inhibitor eligible and who have very low rates of uptake of immunotherapy. This is something that reflects the global team of the ASCO Annual Meeting talking about disparities and improving access to treatments in underserved minority populations here in the United States, and also globally, in the developing world, the disparities in terms of access to care are humongous. So, what are your thoughts, Brian? And also, if you could highlight some of the work that you're doing at Columbia about disparities, I think that would be great. Dr. Brain Henick: Absolutely! I think access to medications is a really humbling topic for those of us who are involved in developmental therapeutics, particularly with the transformational impact we've seen with the advent of immunotherapy over the last decade-plus. Dr. Ravikrishna's presentation is therefore extremely important. He described very low rates of uptake of immunotherapy by indication. And perhaps most strikingly, the discrepancy in uptake by patients' ability to pay for therapy with the vast majority of immunotherapy received by those who are private is very concerning. Even if the definition of restricted access was permissive, for example, I didn't see mention of the cancer stage as an eligibility factor, the fact that this represents a single referral center's data doesn't bode well for uptake elsewhere. So, I think we need to continue to work as a field on prioritizing strategies to help overcome these gaps, but good quality data such as this study is an important first step. And to that point, Vamsi, I'm very excited to be working with you in collaboration on an observational study for patients with lung cancer from underserved minority populations with lung cancer in New York City so that we can better characterize access to care, efficacy, and toxicity in this population. Dr. Vamsi Velcheti: Thank you, Brian. I'd really like to thank you for sharing your valuable insights with us today on the ASCO Daily News Podcast. We really appreciate it. Brian, thank you so much for joining us. Dr. Brain Henick: My pleasure. Thanks for having me. Dr. Vamsi Velcheti: And thank you to all our listeners for joining in today. You will find links to all the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you so much.     Disclosures: Dr. Vamsi Velcheti: Honoraria: Honoraria Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline Dr. Brain Henick: None disclosed. Disclaimer: The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Dr. Neeraj Agarwal, of the University of Utah Huntsman Cancer Institute, tells host Dr. John Sweetenham, of the UT Southwestern Harold C. Simmons Comprehensive Cancer Center, about the first study to examine the quality of diagnosis and treatment of breast cancer in sex and gender minority patients and other key studies on disparities associated with access to clinical trials and rising drug costs.  Transcript Dr. John Sweetenham: Hello, I'm John Sweetenham, the associate director for Clinical Affairs at UT Southwestern Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News podcast.  I'm delighted to welcome my friend and colleague Dr. Neeraj Agarwal, the director of the Genitourinary Cancers Program and a professor of medicine at the University of Utah's Huntsman Cancer Institute. Dr. Agarwal also serves as editor-in-chief of the ASCO Daily News.  Today, he'll be sharing his insights on compelling studies that will be featured at the 2022 ASCO Annual Meeting, addressing access to clinical trials, disparities associated with high deductible health plans, rising drug costs, and more.  Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcripts at asco.org/podcasts.  Neeraj, it's great to have you back on the podcast.  Dr. Neeraj Agarwal: Thanks, John.  Dr. John Sweetenham: Neeraj, let's begin with Abstract 6503. This study looks at the impacts of high deductible health plans on delays in metastatic cancer diagnosis. What do you think about this study and why should it be on our radar?  Dr. Neeraj Agarwal: Well, John, in high deductible health plans, patients are liable for the cost of all cancer-related care, with the exception of screening tests, until their annual deductible is met. Due to increased out-of-pocket costs, patients may postpone seeing a physician for concerning symptoms or diagnostic testing, leading to delayed diagnosis.  So, in this study, Mr. Nicholas Trad and J. Frank Wharam assessed the impact of high deductible health plans on the timing of metastatic cancer detection.  The authors leveraged a nationally representative cohort of more than 340,000 privately insured members whose employers mandated a switch from a low deductible of less than $500 plan to a high deductible plan of more than $1,000.  So, the group consisted of more than 1 million individuals in a contemporary time frame, whose employers offered only low deductible plans. Participants were matched based on multiple baseline characteristics, time to metastatic cancer diagnosis, and the before and after switching to high deductible health plans was investigated using a weighted Cox proportional-hazards model.  After matching, there were no systematic differences between the 2 groups with regards to baseline characteristics, and there were no differences in time to metastatic cancer diagnosis prior to the switch to high deductible health plans.  However, after the employer-mandated switch to the high deductible health plans, these participants had lower odds of metastatic cancer diagnosis, which was significant, statistically speaking, and indicates delayed detection of metastatic cancer diagnosis relative to the control group.  Dr. John Sweetenham: This is certainly concerning data, Neeraj. What's your key takeaway from this study?  Dr. Neeraj Agarwal: So, the key takeaway from the study is that compared with conventional health plans, high deductible health plans are associated with delayed detection of metastatic cancer, implying that patients postpone seeking care for concerning symptoms or even defer diagnostic testing when they're exposed to high-cost sharing.  Dr. John Sweetenham: Thanks, Neeraj. So, let's continue with this theme of the financial burden of cancer care for our patients. Of course, we're all aware of the rising costs of targeted oral therapies, and this was addressed in Abstract 6504, where the study looks at the rising costs of targeted oral treatments among Medicare beneficiaries. And the study reported a substantial increase in the total cost and out-of-pocket costs of these medicines. Can you tell us more about this abstract?  Dr. Neeraj Agarwal: Yes! So, due to the rapidly rising cost of targeted oral anticancer medicines, Drs. Meng Li and Ya-Chen T. Shih examined recent trends and the financial burden of these oral medicines among patients with cancer with Medicare Part D insurance. So, eligible patients in the SEER-Medicare database had to be 65 years and older and had to have one primary cancer diagnosis.  The investigators estimated the trends in the share of patients who used targeted oral anticancer medicines, the percentage of users reaching catastrophic coverage, and the total and patient out-of-pocket spending on these medicines in the catastrophic phase in a year.  So, from 2011 to 2016, the uptake of these oral anti-cancer medicines increased from approximately 4% to 9%. The percentage of those who reached catastrophic coverage increased from 55% to 60%.  Among those who reached the catastrophic phase, the mean total annual gross spending on oral anti-cancer medicine increased 4-fold from approximately $16,000 to $64,000. And the mean out-of-pocket spending for the patients rose from approximately $600 to $2600.  Dr. John Sweetenham: Yes, this is more evidence that the financial toxicity generated from an increase in spending and out-of-pocket costs is going to have serious impacts on our patients. Would you agree with that, Neeraj?  Dr. Neeraj Agarwal: Yes, John. The key takeaway from this study is that the financial burden of these oral anti-cancer medicines continues to increase. In the relatively short period of time, we see here, 5 years from 2011 to 2016, there was a 4-fold increase in the total cost and out-of-pocket cost of these medicines. And in my view, these findings warrant immediate actions to rein in drug prices and cap out-of-pocket spending for our patients.  Dr. John Sweetenham: Absolutely. It's very difficult to know where this will end unless we see some kind of slowdown in these rising costs. I'm going to change gears just a little bit now to address the access to clinical trials, which is the subject of Abstract 6505.  This study looks at the implementation of the Affordable Care Act Medicaid expansion, which was associated with an almost threefold increase in the proportion of patients using Medicaid in cancer clinical trials by early 2020. What are your thoughts on this study?  Dr. Neeraj Agarwal: As you said, the Affordable Care Act Medicaid expansion resulted in increased use of this platform across the nation. However, its impact on access to clinical trials has not been examined.  So, in this study, Dr. Joseph Unger and Dr. Dawn Hershman examined the number and proportion of patients insured by Medicaid at enrollment over time using data from the SWOG Cancer Research Network.  In addition, they also examined all patients, 18 to 64 years old, enrolled in treatment trials between 1992 to 2020 using Medicaid versus private insurance.  So, the implementation of the Affordable Care Act Medicaid expansion was associated with a nearly threefold increase from 7% to 21% in the proportion of patients using Medicaid in cancer clinical trials by early 2020.  The increase per year of Medicaid uses for patients in these treatment trials from states that implemented the Affordable Care Act Medicaid expansion was 27% compared to 7% for patients from other states who did not implement this platform of Affordable Care Act Medicaid expansion.  So, the key takeaway from the study is that better access to clinical trials for more vulnerable patients is critical to improving confidence in how generalizable these trial findings are. In addition, these results suggest that the recently enacted Cancer Treatment Act may continue to improve access to clinical trials for those with Medicaid insurance or those who are vulnerable patients.  Dr. John Sweetenham: Yes, I think this is a really important study which adds to the growing literature on the benefits of the Affordable Care Act and Medicaid expansion on cancer care in general, in this case, specifically related to clinical trials. So, so important, I think.  On that theme of equity, I think the next 2 abstracts we're going to discuss address specific aspects of equity, which I think are both interesting and really important. So, Abstract 6510 has interesting research which conveys an urgent need to ensure equitable patient-reported access and implementation and to address the greater reported symptom burden among minority patients. Why do you think this study is important?  Dr. Neeraj Agarwal: The routine collection of patient-reported outcomes for patients with cancer is an evidence-based practice and a critical component of high-quality cancer care, but the real-world adherence and reporting patterns are poorly understood.  In this study, Dr. Samuel Takvorian and Dr. Ravi Parikh examined differences in adherence to the collection of patient-reported outcomes and reported symptoms by race and ethnicity.  This was a retrospective cross-sectional study using de-identified electronic health record data from an National Cancer Institute (NCI)-designated Comprehensive Cancer Center. The participants included adults seen in follow-up at 1 of the 2 medical oncology practices—one was in academics and one was in the community—from June 2019 to February 2020. Using ordinary least-squares regression, the authors modeled patient adherence as a function of race or ethnicity, and this was adjusted for age, sex, insurance, median area income, ECOG, performance status, and many other patient-related characteristics.  The results show that adjusted mean PRO adherence and reported symptoms varied by race and ethnicity, with Black and Hispanic patients being less likely to complete PRO questionnaires, but reporting significantly higher symptom burden compared to the White patients.  Dr. John Sweetenham: Right. So, it seems that more work is needed to ensure equitable access and adherence to PRO questionnaires so we can better address the symptom burden of our minority patients.  Dr. Neeraj Agarwal: Correct, John. In this large cohort reflecting real-world PRO collection patterns, Black and Hispanic patients were less likely than White patients to complete these PRO questionnaires, but more likely to report more severe symptoms. And I think there is an urgent need to ensure equitable PRO access and implementation and to address the greater reported symptom burden among minority patients.  Dr. John Sweetenham: Let's continue the theme of health equity and cancer care equity into the use of telemedicine. Of course, we saw a massive expansion of telemedicine for patients with cancer during the COVID-19 pandemic.  But studies are emerging now to show that there have been substantial disparities among the Black, uninsured, non-urban, and less affluent patients who are less likely to use telemedicine services.  Abstract 6511 reminds us that telemedicine may expand access to specialty care, but the proliferation of these services may widen cancer care disparities if vulnerable populations don't have equitable access. Can you tell us more about this abstract?  Dr. Neeraj Agarwal: These are indeed very interesting findings, John. The COVID-19 pandemic was associated with declines in in-person clinical visits, with a concurrent increase in the use of telemedicine.  In this study, Dr. Gregory S. Calip assessed demographic and socioeconomic factors associated with telemedicine use among patients initiating treatment for 21 common cancers at community oncology clinics.  This was a retrospective study and made use of the nationwide Flatiron electronic health record derived de-identified database of patients with cancer. The authors focused on differences in telemedicine use across race and ethnicity, insurance coverage, rural versus urban areas, and socioeconomic status.  They used logistic regression models for this analysis, which was adjusted for clinical characteristics to examine differences in telemedicine use among these different cohorts.  Results indicate Black patients were significantly less likely to use telemedicine services compared to White patients. Telemedicine use was also significantly lower among patients without documented insurance than well-insured patients. It was also lower in patients from rural and suburban areas versus patients who were living in urban areas. Lastly, telemedicine use was significantly lower in patients in the least affluent areas than those in the most affluent areas.  So, during the COVID-19 pandemic, nearly one-fifth of patients initiating cancer treatment using telemedicine services—among these patients, we see substantial disparities. So, Black, uninsured, non-urban, and less affluent patients were less likely to use telemedicine services.  So, the take home message from this study is that while telemedicine may expand access to care, the proliferation of these services may actually widen cancer care disparities if vulnerable populations do not have equitable access to these services.  Dr. John Sweetenham: Thanks, Neeraj. So, the final study that we'll discuss today also looks at another aspect of disparities, and that's Abstract 6517. It's a case-controlled study of health care disparities in sex and gender minority patients with breast cancer. What are the key takeaways from this study?  Dr. Neeraj Agarwal: Disparities and the quality of diagnosis and treatment of breast cancer in sex and gender minority populations are largely undefined. Only 24% of studies funded by the National Cancer Institute capture data on sexual orientation and only 10% capture data on gender identity.  In this case-control study, Drs. Eric Eckhert and Allison W. Kurian matched sex and gender minority patients with breast cancer to cisgender heterosexual controls in the Stanford University health care database. Ninety-two sex and gender minority patients were identified who were then matched by year of diagnosis, age, stage of cancer, presence of estrogen receptor (ER), and HER-2/neu receptor status to cisgender heterosexual controls within this database.  Additional data on demographics, diagnosis, treatment, and relapse were then manually abstracted from the electronic health care records. The sex and gender minority cohort were comprised of 80% lesbians, 13% bisexuals, and 6% transgender men.  One of the most pertinent findings was a significant, almost twice as much delay in time to diagnosis from the onset of symptoms in these minority patients versus control. Although there was no difference in the receipt of surgery or surgical radiation or new adjuvant therapy, sex, and gender minority patients were significantly less likely to undergo chest reconstruction surgery, and if they were estrogen receptor-positive, they were significantly less likely to complete at least 5 years of ER directed therapy.  Please also note that sex and gender minority patients used more alternative medicine, had a higher rate of documented refusal of recommended oncology treatments, and they experienced a higher recurrence rate.  So, the key takeaway from this study is that—this is the first study, I really want to congratulate the investigators who examined the quality of diagnosis and treatment of breast cancer in sex and gender minority patients. Several novel potential health care disparities are identified in these patients, which should be further evaluated in population-based studies to inform further interventions.  Dr. John Sweetenham: Neeraj, it's always a pleasure to talk with you and have an opportunity to spend some time with you. Thanks very much for sharing your insights on these compelling studies today. Our listeners will find the links to these abstracts in the transcripts of this episode.  Dr. Neeraj Agarwal: Thanks, John.  Dr. John Sweetenham: And thanks to our listeners for your time today. If you're enjoying the content on the ASCO Daily News podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.    Disclosures:  Dr. John Sweetenham  Consulting or Advisory Role: EMA Wellness  Dr. Neeraj Agarwal:  Consulting or Advisory Role: Pfizer, Medivation/Astellas, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Merck, Novartis, lily, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences    Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, ORIC Pharmaceuticals, CRISPR therapeutics, and Arvinas     Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. 

Most Americans consume dietary sodium exceeding age-specific government-recommended targets of 1,500–2,300 mg/day per person. Americans consume on average 50% more than the recommended limit for those age 14 years and older which could have profound impacts on later health outcomes.It's not the salt shaker - The majority (71%) of US dietary sodium comes from restaurant and packaged foods.Why is it important? Excess sodium intake contributes to hypertension and cardiovascular disease, which is the leading cause of death in the United States.For years, experts and the government have been recommending a reduction in the amount of sodium in our diets and recently – October, 2021 – the FDA announced voluntary sodium reduction goals for Commercially Processed, Packaged, and Prepared Foods.A major announcement aimed at reducing the burden of diet-related chronic disease, improve #publichealth and advance health equity...Today to enlighten us on voluntary sodium reduction goals is our guest, Robin McKinnon, PhD, MPA, Senior Advisor for Nutrition Policy at the Food and Drug Administration (FDA) Center for Food Safety and Applied Nutrition (CFSAN). Dr. McKinnon works to advance the FDA's nutrition-related activities across CFSAN, including those related to sodium reduction. Prior to joining the FDA, Dr. McKinnon was a Health Policy Specialist at the National Cancer Institute (NCI), National Institutes of Health. At NCI, Dr. McKinnon led initiatives to advance policy-relevant research on diet, obesity and physical activity. Dr. McKinnon has a Ph.D. in Public Policy and Administration from the George Washington University and a Masters in Public Administration from Harvard University.

Effects of strawberries on bone biomarkers in pre- and stage 1-hypertensive postmenopausal women Florida State University Postmenopausal women experience an increase in bone remodeling with the rate of bone resorption superseding the rate of bone formation. This results in a net bone loss with a subsequent increased risk for osteoporosis and fractures. Strawberries are rich in polyphenols, which have been shown to have anti-hypertensive and bone-protective properties. Thus, we examined whether daily intake of strawberries would positively affect biomarkers of bone metabolism in postmenopausal women with pre- and stage 1-hypertension. After eight weeks, osteocalcin increased in the 50 g FDSP group with a large effect size (d = 0.6) when compared to the placebo-control group. Adiponectin increased by 5% and 6% in the 25 g and 50 g FDSP groups, respectively, while it declined in the placebo-control group by 25% (P = 0.03 for time-by-treatment interaction). Our findings suggest that consumption of 25 g FDSP increases IGF-1 in postmenopausal women with pre- and stage 1-hypertension.    Dietary supplement use by individuals living with and beyond cancer University College London, December 20, 2021 New research indicates that many individuals living with and beyond cancer use dietary supplements, often with the belief that the products will reduce the risk of cancer recurrence. Published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings reveal a need for health care professionals to provide advice and clarity to patients about the appropriate use of dietary supplements. To explore factors associated with dietary supplement use in cancer survivors, Rana Conway, PhD, RNutr, of University College London (UCL), and her colleagues studied 1,049 adults who had been diagnosed with breast, prostate, or colorectal cancer in the United Kingdom.  Among the major findings: 40% of participants took dietary supplements. 19% of participants believed that dietary supplements could reduce the risk of cancer recurrence. Women, participants meeting five-a-day fruit and vegetable recommendations, and those believing that dietary supplements were important for reducing the risk of cancer recurrence were more likely to use dietary supplements. Participants with obesity were less likely to use dietary supplements. Fish oils were the most commonly used dietary supplements, taken by 13% of participants. Calcium with or without vitamin D were the supplements most commonly used by individuals with breast cancer, taken by 15%.   Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial Nutrition Research Centre Ireland, December 20, 2021 Accumulating evidence suggests that omega-3 fatty acids (ω-3FAs), carotenoids and vitamin E can improve cognitive performance. However, their collective impact on cognition has not yet been investigated in healthy individuals. This study investigated the combined effect of ω-3FA, carotenoid and vitamin E supplementation on the cognitive performance of older adults. Methods Cognitively healthy individuals aged ≥65 years consumed daily 1 g fish oil (of which 430 mg docosahexaenoic acid, 90 mg eicosapentaenoic acid), 22 mg carotenoids (10 mg lutein, 10 mg meso-zeaxanthin, 2 mg zeaxanthin) and 15 mg vitamin E or placebo for 24 months in a double-blind, placebo-controlled, randomised clinical trial. These results support a biologically plausible rationale whereby these nutrients work synergistically, and in a dose-dependent manner, to improve working memory in cognitively healthy older adults. Increasing nutritional intake of carotenoids and ω-3FAs may prove beneficial in reducing cognitive decline and dementia risk in later life.   A high-fiber diet may improve the response of melanoma patients to immunotherapy University of Texas and  National Cancer Institute, December 23, 2021 A diet rich in fiber may help some people being treated for melanoma respond to immunotherapy treatment by influencing the gut microbiome, according to a new study led by researchers at the Center for Cancer Research at the National Cancer Institute (NCI), part of the National Institutes of Health, and the University of Texas MD Anderson Cancer Center.  Among patients with advanced melanoma who underwent immunotherapy with immune checkpoint blockers, those who consumed at least 20 grams a day of dietary fiber survived the longest without their disease progressing. In contrast, use of probiotic supplements appeared to lessen somewhat the effectiveness of immune checkpoint blocker regimens. Probiotics are live microorganisms typically consumed as a supplement to improve gut health. Among the 128 patients whose dietary fiber intake was known, those who reported consuming at least 20 grams of dietary fiber per day (an amount the researchers designated as "sufficient" for the purposes of this study) lived longer without their cancer progressing than those who consumed less dietary fiber. Every 5-gram increase in daily dietary fiber intake corresponded to a 30% lower risk of progression of the disease. Dr. Trinchieri noted that one possible mechanism through which dietary fiber exerts its beneficial effect is by increasing the types of bacteria in the gut, such as Ruminococcaceae, that produce high levels of certain short-chain fatty acids that have an antitumor effect.   Could meditation strengthen your immune system? University of Florida's College of Medicine, December 23, 2021 Meditation done at an intense level may bring a significant boost to the inner workings of your immune system. That analysis suggested that meditation boosted the activity of hundreds of genes known to be directly involved in regulating immune response. But the researchers stressed that their study involved 10-hour daily marathon meditation sessions conducted for eight straight days in total silence. In the real world, most people would be hard-pressed to replicate those methods.  The eight-day retreat provided all participants with vegan cuisine, and all followed a regular sleep schedule. Meditation sessions lasted 10 hours a day and were conducted in silence. The result: Three months after the retreat's conclusion, Chandran and his colleagues found an uptick in activity involving 220 immune-related genes, including 68 genes engaged in so-called "interferon signaling." The study authors pointed out that such signaling can be key to mounting an effective defense against various health conditions—including cancer, multiple sclerosis or even COVID-19—given that interferon proteins effectively act as immune system triggers.  Among seriously ill COVID-19 patients in particular, Chandran noted, insufficient interferon activity has been cited as a problem.  He explained that nearly all (97%) of interferon "response genes" were found to be activated following the mediation retreat. But relying on publicly available gene activity data derived from COVID-19 patients, Chandran and his colleagues reported that figure to be 76% among those with mild COVID illness, and just 31% among the most severe cases. At the same time, the investigators found that while inflammation-signaling gene activity remained stable following in-depth meditation, such signaling shot up among severely ill COVID-19 patients.   Even light-intensity exercise might reduce dementia risk Yonsei University College of Medicine (South Korea), December 22, 2021 In a new study, researchers have identified an association between light-intensity physical exercise in older adults and a reduced risk of dementia. In the present study, researchers investigated whether there was an association between doing light-intensity physical exercise and a reduced risk of developing dementia in older adults. The study involved 62,286 participants who were 65 years or older, did not have a dementia diagnosis, and had medical records in the Korean National Health Insurance Service database.  Researchers gathered data between January 2009 and December 2012 and tracked the participants until the end of December 2013. They completed data analysis from July 2020 to January 2021. After a median follow-up period of 42 months, the researchers noted how many participants developed dementia. They found that insufficiently active participants had a 10% reduced risk of developing dementia compared with inactive participants.  Active participants had a 20% reduced risk, while highly active participants had a 28% reduced risk.   Fast-food consumption linked to lower test score gains in 8th graders The more children ate in 5th grade, the slower their academic growth by 8th grade Ohio State University, December 22, 2021   The amount of fast food children eat may be linked to how well they do in school, a new nationwide study suggests. Researchers found that the more frequently children reported eating fast food in fifth grade, the lower their growth in reading, math, and science test scores by the time they reached eighth grade. Students who ate the most fast food had test score gains that were up to about 20 percent lower than those who didn't eat any fast food, said Kelly Purtell, lead author of the study and assistant professor of human sciences at The Ohio State University. The results remained even after the researchers took into account a wide variety of other factors that may have explained why those with high fast-food consumption might have lower test scores, including how much they exercised, how much television they watched, what other food they ate, their family's socioeconomic status and characteristics of their neighborhood and school. This study included about 11,740 students. They were tested in reading/literacy, mathematics and science in both fifth and eighth grades. They also completed a food consumption questionnaire in fifth grade.Children who ate fast food four to six times per week or every day showed significantly lower gains in all three achievement areas compared to children who did not eat any fast food the week before the survey. However, children who ate fast food just one to three times a week had lower academic growth compared to non-eaters in only one subject, math.

Clinical trials represent the primary means to test new drugs before they become approved by the FDA for sale and marketing as a standard of care. The purpose of these trials is to test the safety and efficacy of new drugs and their combinations. Clinical trials must be performed with the highest ethical standards and must include geographically, genetically and socio-economically diverse populations. Trials provide completely free care for all participants, ensuring that any patient can participate. However, the vast majority of cutting-edge trials are performed in elite academic tertiary care centers, requiring patients not living in the immediate vicinity to undergo burdensome travel and long stays away from home. The Guardian Research Network was developed to address these issues by bringing novel trials to community health systems where most patients are treated, effectively democratizing clinical trial access. A new digital approach was developed to consenting patients, and collecting and reporting clinical data, and a network was formed using centralized approaches to save time and expense. Real-world data is used to submit comparator control arms to the FDA to support rapid drug approvals. Timothy J. Yeatman, M.D. is an adjunct professor of surgery at the University of Utah, where he has an active National Cancer Institute (NCI)-funded laboratory, and he is a member of the Cell Response and Regulation Program of the Huntsman Cancer Institute (HCI). He has spent the past two and a half years directing the development of an integrated cancer program for Intermountain Healthcare and its 24 hospitals, and coordinating collaborations with the University of Utah and HCI. He recently joined Phenome Health as its chief clinical officer in charge of identifying and accruing 1million participants in the Beyond the Human Genome Project (BHG). MLF ORGANIZER Robert Lee Kilpatrick NOTES MLF: Health & Medicine SPEAKERS Dr. Timothy J. Yeatman M.D., Adjunct Professor of Surgery, University of Utah; Chief Clinical Officer, Phenome Health; Dr. Robert Lee Kilpatrick Ph.D., Chair, Health & Medicine Member-Led Forum—Moderator In response to the COVID-19 pandemic, we are currently hosting all of our live programming via YouTube live stream. This program was recorded via video conference on December 7th, 2021 by the Commonwealth Club of California. Learn more about your ad choices. Visit megaphone.fm/adchoices

Clinical trials represent the primary means to test new drugs before they become approved by the FDA for sale and marketing as a standard of care. The purpose of these trials is to test the safety and efficacy of new drugs and their combinations. Clinical trials must be performed with the highest ethical standards and must include geographically, genetically and socio-economically diverse populations. Trials provide completely free care for all participants, ensuring that any patient can participate. However, the vast majority of cutting-edge trials are performed in elite academic tertiary care centers, requiring patients not living in the immediate vicinity to undergo burdensome travel and long stays away from home. The Guardian Research Network was developed to address these issues by bringing novel trials to community health systems where most patients are treated, effectively democratizing clinical trial access. A new digital approach was developed to consenting patients, and collecting and reporting clinical data, and a network was formed using centralized approaches to save time and expense. Real-world data is used to submit comparator control arms to the FDA to support rapid drug approvals. Timothy J. Yeatman, M.D. is an adjunct professor of surgery at the University of Utah, where he has an active National Cancer Institute (NCI)-funded laboratory, and he is a member of the Cell Response and Regulation Program of the Huntsman Cancer Institute (HCI). He has spent the past two and a half years directing the development of an integrated cancer program for Intermountain Healthcare and its 24 hospitals, and coordinating collaborations with the University of Utah and HCI. He recently joined Phenome Health as its chief clinical officer in charge of identifying and accruing 1million participants in the Beyond the Human Genome Project (BHG). MLF ORGANIZER Robert Lee Kilpatrick NOTES MLF: Health & Medicine SPEAKERS Dr. Timothy J. Yeatman M.D., Adjunct Professor of Surgery, University of Utah; Chief Clinical Officer, Phenome Health; Dr. Robert Lee Kilpatrick Ph.D., Chair, Health & Medicine Member-Led Forum—Moderator In response to the COVID-19 pandemic, we are currently hosting all of our live programming via YouTube live stream. This program was recorded via video conference on December 7th, 2021 by the Commonwealth Club of California. Learn more about your ad choices. Visit megaphone.fm/adchoices

Shazia Ahmad, Senior Director, Head of Patient & Physician Services at UBC, earned a B.S. in physiology and neurobiology from the University of Maryland and has 20+ years of experience in the therapeutic development industry. Shazia is a seasoned thought leader in the rare disease space with a passion for ensuring the patient journey and diagnostic experience is implemented in every program she develops. Shazia has also served as a study coordinator at the National Institutes of Health (NIH). While at the NIH, Shazia coordinated intramural clinical trials across the various institutes, including the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI). Shazia is a thought-leader in patient advocacy, with a desire to improve healthcare and integrate successful solutions that bring optimal access and diversity to clinical trials. Shazia serves as a Board Advisor on the HPV Alliance, a non-profit organization that helps to advance the prevention of HPV-related cancers through education, advocacy and research. Her passion for the diverse people of the rare disease community continues to drive her work though the implementation of patient advocacy initiatives. Connect with her on LinkedIn: https://www.linkedin.com/in/shaziakahmad/ Follow her on Twitter at: @ShaziaKAhmad

Dr. Cheryl Willman was named executive director of Mayo Clinic Cancer Programs, and director of the Mayo Clinic Cancer Center in May. In this role, Dr. Willman is leading the expansion and strategic development of Mayo Clinic Cancer Center locations in Arizona, Florida and Minnesota, as well as newly developing Mayo Clinic global cancer programs in London and Abu Dhabi, United Arab Emirates.Mayo Clinic Cancer Center is designated by the National Cancer Institute (NCI) as a comprehensive cancer center. At comprehensive cancer centers, staff coordinate innovative cancer care delivery for patients; conduct team-based cancer research to develop better means to prevent, detect and treat cancer; involve communities and patients in research; and train the next generation of cancer health professionals. Mayo Clinic Cancer Center offers its patients access to hundreds of clinical trials in all phases that test new and improved cancer treatments. "We have a menu of over 300 cancer clinical trials every year that are testing new drugs and bringing treatments to patients," says Dr. Willman. "Cancer clinical trials are essential to advancing our knowledge in cancer care."Work is underway at Mayo Clinic Cancer Center to grow the Cancer Care at Home program and engage local communities, which can help address disparities in health care. Other initiatives include making advances in radiation therapy techniques and using genomics to develop individualized care for patients.Mayo Clinic Cancer Center also is expanding the use of patient navigators, allowing cancer patients to have one point of contact to help them navigate the complexities of cancer care that often involves many specialists. "For a breast cancer patient, for example, that would include breast cancer surgeons, medical oncologists who give chemotherapy, radiation oncologists who give radiation, but also physical medicine and rehabilitation, nutrition, psychosocial support, and access to clinical trials," says Dr. Willman. "A patient navigator becomes the primary contact person for a patient we're caring for and truly navigates them through all of their providers."On the Mayo Clinic Q&A podcast, Dr. Willman discusses the innovations taking place at Mayo Clinic to improve cancer care for patients.

Dr. Gabrielle Rocque, chair of the 2021 ASCO Quality Care Symposium, breast oncologist and health services researcher at the University of Alabama at Birmingham, and symposium chair-elect, Dr. Stephanie Wheeler, professor in the Department of Health Policy and Management at the University of North Carolina at Chapel Hill, discuss key interventions in quality care and compelling patient perspectives presented at #ASCOQLTY21. Transcript ASCO Daily News: Welcome to the ASCO Daily News podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. On today's episode, we'll discuss promising interventions to improve the quality of care for patients and survivors and other key takeaways from the 2021 ASCO Quality Care Symposium. I'm delighted to welcome the chair and chair-elect of the [ASCO Quality Care] Symposium, Dr. Gabrielle Rocque and Dr. Stephanie Wheeler, for this discussion. Dr. Rocque is a breast oncologist and health services researcher. She is also associate professor of medicine in the Division of Hematology and Oncology and Gerontology, Geriatrics, and Palliative Care at the University of Alabama at Birmingham. Dr. Wheeler is a professor in the Department of Health Policy and Management at the University of North Carolina at Chapel Hill. She also serves as associate director of community outreach and engagement at the UNC Lineberger Comprehensive Cancer Center. My guests' full disclosures are available in our show notes, and disclosures relating to all episodes of the podcast are available on our transcripts at asco.org/podcasts. Dr. Rocque and Dr. Wheeler, thanks for being on the podcast today. Dr. Gabrielle Rocque: Thank you for having us. ASCO Daily News: Dr. Wheeler, it was wonderful to have a hybrid event this year, with people participating in person in Boston and virtually. This is surely a sign of things to come. Can you tell us about some of the most important interventions in quality improvement that were presented at the [ASCO Quality Care] Symposium? Dr. Stephanie Wheeler: Absolutely, and thank you so much for hosting us. It was a really terrific [ASCO Quality Care] Symposium. And the fact that we had hybrid engagement from investigators all over the country and internationally was really exciting. There's a couple of intervention classes, if you want to call it that, that I think were particularly inspiring and interesting to me. The first were sets of interventions that focused on strategies to improve goals of care conversations and advanced care planning directives for patients with cancer or people with terminal illness in particular. And I just wanted to highlight a couple of those that I thought were particularly innovative. One was Abstract 8, which focused on using computer modeling and care coaches to increase advanced care planning conversations for people with advanced cancer. And this was presented by Dr. Divya Gupta. And it was just a wonderful example of how we can utilize technology and also care coaches. And in many cases, these don't necessarily have to be clinicians. They sometimes can be community health workers and others who can help direct those conversations and make it more comfortable for people living with advanced disease, and also their families, to consider next steps. In a similar vein, there were two other presentations--Abstract 1 delivered by Dr. Manali Patel and Abstract 2 delivered by Dr. Divya Parikh--that also utilized a similar model in a different care setting. And in those cases, the care settings ranged from VA to integrated health care settings. And we even had a conversation about how to do this work in community rural oncology practices. And I think that this kind of intervention has the potential for translation across a variety of settings. And the next steps are going to be figuring out exactly how to implement it in these settings. So, that's one class that I thought was particularly interesting. And I just want to highlight another group of interventions and studies that I found really innovative. And those were the presentations about hospital at-home models and how we can better deliver oncology care in the comfort of individuals' homes. And I thought Dr. Cardinale Smith did a great job from Mount Sinai describing the landscape of those interventions and the future for this kind of care delivery (“Overview of Programs and Ethics”). ASCO Daily News: Excellent. Great to hear about those promising new approaches. Dr. Rocque, the [ASCO Quality Care] Symposium captured many trends in quality care, including patient-reported outcomes measurement as an important way to monitor quality of care and patients' experiences. Can you highlight the studies that will help inform our listeners about how to integrate patient-reported outcomes into real-world settings? Dr. Gabrielle Rocque: Yeah. This was a major topic of the conference this year to think about how patient-reported outcomes are informative both in traditional research settings and in real-world settings. So, I was really intrigued by the Abstract 154 by Joy Jarnagin. And that abstract talked about how the changes in patient-reported outcomes actually had a very strong association with patients' treatment response, and in fact, was even more informative than those patients' tumor markers and I think show a novel way that patient-reported outcomes can be used. We also saw some more traditional abstracts on patient-reported outcomes. I'd like to highlight Abstract 152 by Valerie Lawhon, which really used patient-reported outcomes to identify patients' experience and their mental health outcomes during the COVID-19 pandemic, and I think provided us some really important insight into the experiences of our patients. And then as you mentioned, there is a lot of focus on real-world settings and how to transition from typical research patient-reported outcomes to a more broad scale implementation. And the session implementing PROs in oncology practice was really outstanding in terms of considering how this can be done. So, Dr. Terry Mulvey from Massachusetts General Hospital presented their experience on how to get these patient-reported outcomes into routine care, and what are some of the challenges associated with that, and how did they have to adapt to make sure that this was doable in real-world settings (“Challenges to Getting Started in a Practice Setting”). I was also impressed with the study by Dr. Raymond Osarogiagbon on the potential populations where there can be barriers of care and their study looking at an intervention in which they're implementing patient-reported outcomes over a wide variety of different practice types across the country (“Potential Populations Where This Can Be a Barrier to Care”). And I think these early insights also pointed us to future questions. Dr. Wynne Norton did a wonderful job of outlining some of the future questions that are likely to come up as we move into an era where patient-reported outcomes are a part of standard of care, and really think about how do we refine these for maximal benefit (“Overview of Current Strategies”). So, I think all of these sessions were highlighting the promise of patient-reported outcomes, as well as the future questions in this space. ASCO Daily News: Excellent. As a specialist in gerontology, geriatrics, and palliative care, please tell us about new approaches that oncologists should be aware of as they strive to provide high quality care for older patients and those receiving palliative care. Dr. Gabrielle Rocque: Absolutely. So, we've talked a bit about the patient-reported outcomes. And I think we'd be remiss in not highlighting the presentation on geriatric assessment--the presentations on the geriatric assessments into clinical practice by Dr. [Rawad] Elias (“Incorporating Geriatric Assessments Into Practice”). And I think this highlights another opportunity for us to move the field forward and take better care of our older adults. In terms of palliative care, there were multiple very informative abstracts. Dr. Wheeler has highlighted a few in the space of care guides or lay health coaches providing support in advanced care planning. In addition, we saw an interesting discussion of caregiver interventions for patients that are receiving--with cancer treatment by Dr. Nick Dionne-Odom (“Caregiver Interventions”). And I think it's important that we remember both the patients and the caregivers who are affected by cancer and by the amount of work that has to be done to support a patient with cancer going through their journey. ASCO Daily News: Absolutely, so important to remember caregivers and their needs and resources that could be available to them as well. Dr. Wheeler, financial toxicity is an enormous concern for many patients and their families, and the oncology care community has been trying for some time to figure out how best to address the concerns of patients and the health care system. Are there any new interventions that we should be aware of? Dr. Stephanie Wheeler: Yes, and I think that the [ASCO Quality Care] Symposium was an opportunity to hear about several of those. And some of them didn't make it onto the main stage but were featured in abstract sessions and poster sessions. So, as we're all well aware, financial toxicity is a multidimensional set of constructs that includes patients and their family's material out-of-pocket burden, as well as the psychological distress and potentially harmful care altering behaviors that financial hardship induces. And so, we continue to hear at the [ASCO Quality Care] Symposium multiple talks about the strain that patients are undergoing, including the non-medical hardship that's introduced by a cancer diagnosis. And that was really interesting, and I think important to document. But I think that where the field is moving is more towards interventions, both behavioral interventions and systems interventions, multilevel approaches to dealing with the hardship itself as well as the importance of policy. So, there were several abstracts that talked about the introduction of biosimilars and generics and how that affected price of many of the oncologic drugs available on the market. And frankly, the message is a bit discouraging. Prices continue to rise. And in some cases, the price increases are not limited to pharmacologic products. In some cases, we saw abstracts presenting the increased cost of surgery, of outpatient care appointments, and things like that as well. So, we're not going to fix the problem by managing drug pricing alone. In terms of patient and family-directed interventions, I thought that there were some interesting abstracts. I want to highlight a number 53--or excuse me, Abstract 43 by Melissa Beauchemin that focused on the existence of hospital specialty pharmacies and partnering with freestanding care coordination organizations to improve access to oncology medications, as well as Abstract 96 presented by Ms. Rachel Marquez which was focused on resolving transportation disparities and access to cancer treatments. These kinds of interventions are obviously patient directed but have tremendous potential. And then I also want to just note a couple of additional studies that are ongoing that are important to recognize in this field. There are at least five National Cancer Institute (NCI)-funded R01 trials underway right now investigating the role of financial navigation and various iterations of it in different care settings. So, I think we will want to look to this meeting as an opportunity to hear about that work as it moves forward. And how that work is implemented is going to be vital, because the types of care settings where it's being done--ranging from AYA populations in Utah, to urban populations in Washington state, to integrated care organizations in Northern California, all the way to parts of rural North Carolina--we're going to see a diversity of outcomes and different ways in which those types of interventions can manifest in those different studies. I also want to note that the NCI has funded a series of supplements through its Cancer Center Core Grant Initiative that are all focused on identification, timely identification of financial toxicity in practice. And many of the investigators leading that work were attending the [ASCO Quality Care] Symposium, and so that will be important to keep an eye on as we move forward as well. ASCO Daily News: Excellent. Dr. Rocque, let's focus on health equity and access. I'd like to ask you about the session on eliminating barriers to clinical trial access. The presenters of this session shared strategies to directly address inclusion and diversity in cancer care. Can you tell us about approaches that caught your attention? Dr. Gabrielle Rocque: Absolutely. So, this was a really great session talking about clinical trial access and barriers, and particularly as it relates to health equity. And so, in Abstract 74, Dr. Joe Unger presented a really interesting conceptual model that highlighted that the barriers to clinical trial access are not necessarily always at the patient level, but they are at the system level, the provider level. And this framework for considering how do we target in the future our ability to engage patients in clinical trials was really important, and I think was complemented well by the patient perspective from Rick Bangs, who's worked closely with SWOG, in thinking about how do patients view clinical trials and how can we better engage them. And I think folding together these different experiences and models to develop future interventions. I also thought the Abstract 75 looking at survival in the real-world analysis was noteworthy. And in particular, the ability to consider patients who are typically excluded from clinical trials based on their laboratory criteria and potentially having something like chronic kidney disease, and how little data there is on those patients who actually, in this study, had different outcomes after chemotherapy for breast cancer. I think when you think about clinical trial access and inclusion, I also think you need to think about how we collect our data and how we consider race and other social determinants of health. So, there were a few other abstracts that, although not in this session, I think were incredibly important for us to consider. The first is Abstract 78 by Ms. Niveditta Ramkumar that talked about the association between rurality and race and surgical treatment and outcomes for non-metastatic colon cancer. And so, she talked a bit about the intersectionality between race and rurality, and I think brings up an important topic that we need to think about these constructs, not only as individual constructs but how they impact each other as we consider analysis in the future. And also Abstract 80 by Dr. Kekoa Taparra, which was a really interesting abstract that talked about the disaggregation of Pacific Islanders in major Asian subpopulations to reveal hidden cancer disparities. So, in this abstract, he discussed how we often lump together different populations, potentially because of small numbers, who really may have very different experiences and characteristics. And I think challenges us to move the field forward by identifying populations in groups that are, in fact, very similar to each other and not just pulling this together. And I think that will have an impact on how we view engaging patients in clinical trials, as well as reporting those clinical trial results that allows our providers to understand how the trial results fit for the patient that is sitting in their clinic for whom they're making their decisions. ASCO Daily News: Indeed. Dr. Wheeler, is there anything that you'd like to add on the issue of access to clinical trials? Dr. Stephanie Wheeler: So, there was an abstract that particularly sparked my attention, [Abstract] 79 presented by Dr. Jenny Xiang about the VA Connecticut Cancer Experience, where universal pre-screening and using computer algorithms to identify patients who might be eligible for clinical trials was used. And I think that this is an important approach that can help us rely less on the assumptions and the biases that exist in clinical care practice about whether a patient may or may not participate in a clinical trial, and instead use the vast amounts of information that we know about them in their electronic health record to try to preemptively identify them and approach them. We know that when patients are asked and invited to be part of trials, they are much more likely to say yes than people assume. And this could be a more unbiased way of assessing that eligibility, and then proactively identifying people, ideally, with a trial navigator. I think that would enable us to potentially overcome some of the barriers that exist and that are, frankly, institutionally biased in many cases. ASCO Daily News: Thank you, Dr. Wheeler. Dr. Rocque, the [ASCO Quality Care] Symposium featured an excellent keynote address by Dr. Ben Corn of Hebrew University of Jerusalem (“Integrating Hope – Real Hope! – Into Clinical Oncology”) and a wonderful lecture by Dr. John Cox, who was honored with the Joseph V. Simone award for advancing quality cancer care (“Reshaping Practice: Necessary Trouble”). Can you share some highlights from their talks? Dr. Gabrielle Rocque: Definitely. So, the keynote address by Dr. Ben Corn was perfectly timed for this meeting. I think everyone has had a difficult past 2 years with the pandemic. And his message of the importance of hope really struck a chord with me and many of the attendees, and how this is something that we can strategically work to improve, and that hope is something we can modify and train for. And so, I'm really excited to both hear this lecture and then also see what's to come in the future in this domain of hope-related research. Another session that I would like to highlight as well is Dr. Cox's talk after receiving the Joe Simone Achievement Award. And his lecture highlighted that change is coming. And he emphasized the importance of changing payment structures to be able to improve the quality of care that patients receive and to be able to leverage those changes for infrastructure that allows us to enable our health system to have a more patient-centered approach with many of the types of interventions that we've been talking about here today. So, I think both of those sessions are really must-watch sessions that I would like to highlight today. ASCO Daily News: Excellent. Well, the [ASCO Quality Care] Symposium also heard some compelling patient perspectives. Dr. Wheeler, can you share some of these messages with us? Dr. Stephanie Wheeler: One of the most powerful sessions in the entire meeting was the very first one, which was focused on the metavivor experience (“The Patient Voice: “Metavivors” and Long-Term Survivorship Care”). And I think because part of the intention of the planning committee was to proactively feature patients' voices at this meeting, this particular session was almost entirely comprised of patients and survivors. And living with advanced disease, as we know now, is very different than it was in the past. And we know that patients living with incurable disease may sometimes go on to live 15, 20, 25 years. And their needs are quite different than patients who have early-stage cancer. And so, this session was impactful because it represented a range of experiences. We heard from a caregiver. We heard from a young woman who's living with stage four melanoma, Dr. Tarlise Townsend (“An AYA Perspective”). And one of the things that I took away from this session in particular was that our approaches in the way that we talk to metavivors has to be fundamentally different, that they want providers to be truthful, they want providers to acknowledge the uncertainty and prognosis and the sometimes complex and rapidly changing regimens that may be available for them in terms of dealing with their disease. But they don't want to be condescended to, they don't want to feel like there's information that is being withheld. One of the things that Dr. Townsend shared that was very powerful was that she talked about how her providers, in many cases, outlined an optimistic future for her and would give her maybe unfair expectations about what the future might hold and think about it in terms of the outlier effect. But that's not the case for many people with her condition. And so, she talked about having to do her own death work--and that's her term--and how much time she spent really trying to understand for herself what the future looked like. And it just resonated so much with me. And everybody on this panel had similar stories to share about their experiences. And it reminded me that at the end of the day, we're all human. None of us deal with uncertainty well. None of us deal with death well, or the prospect of death. But the best that we can do in these situations is to be open and honest and straightforward and recognize the fear and the hope and all of that being intermingled, and really respect the person's autonomy and the person's experience and their ability to make plans for themselves going forward. ASCO Daily News: Thank you, Dr. Wheeler. We will have links to these important patient perspectives in the transcript of this episode, as well as the other abstracts discussed today. Dr. Rocque and Dr. Wheeler, thank you very much for sharing these important highlights from the 2021 ASCO Quality Care Symposium. Dr. Stephanie Wheeler: Thank you for having us. Dr. Gabrielle Rocque: Thank you so much. ASCO Daily News: And thank you to our listeners for your time today. If you enjoyed this episode, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclosures: Dr. Gabrielle Rocque: Consulting or Advisory Role: Pfizer, Flatiron Research Funding: Carevive Systems, Genentech, Pfizer Travel, Accommodations, Expenses: Carevive (an immediate family member) Dr. Stephanie Wheeler: Research Funding (institution): Pfizer Foundation Travel, Accommodations, Expenses: Pfizer Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

The Docs celebrate Dr. Karen's appointment to the National Cancer Advisory Board (NCAB) this past week and the impact she hopes to have in this new position. The NCAB advises the director of the National Cancer Institute (NCI) to support research,  training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. Dr. Karen reflects on the the path that has led her to this appointment and how academia has evolved to consider health disparities work important worthy of a seat at the table. Read the official appointment here!--New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com Please take a moment to fill out our survey so we can continue to bring you the content you love! Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

Jim Joyce, co-founder, chairman, and CEO of Sigyn Therapeutics discusses the development of Sigyn Therapy, the company's blood purification technology to overcome the limitations of drugs and other devices to treat Cytokine Storm induced inflammatory conditions that lead to sepsis. He explains the relationship between Cytokine Storm and COVID and how this blood purification technology is an approach that is getting alot of attention right now. He talks about how this technology differs from current blood purification technologies and what the current treatment landscape looks like. #SigynTherapeutics #BloodPurificationTechnology #CytokineStorm James “Jim” Joyce has 30+ years of diverse public market experience, which includes two decades of public company CEO and Corporate Board leadership roles. He is also an inventor or co-inventor underlying 18 pending or issued patents. Prior to establishing Sigyn Therapeutics, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, a therapeutic technology company that he navigated from single shareholder start-up to Nasdaq-traded Company with 8000+ shareholders. During his tenure at Aethlon, Mr. Joyce oversaw the development of the Hemopurifier®, a first-in-class blood purification technology to address life-threatening viruses and cancer-promoting exosomes. Under his leadership, the Hemopurifier® became the first therapeutic candidate to be awarded two FDA “Breakthrough Device” designations and was the first and only device to receive “Emergency Use Authorization” (EAU) approval from both the FDA and Health Canada to treat Ebola virus. Time Magazine named the Hemopurifier® one of the “11 Most Remarkable Advances in Healthcare” and designated the device to its “Top 25 Best Inventions” award list. The Hemopurifier® has since been cleared by the FDA to treat severe COVID-19 infections in a clinical setting. Under Mr. Joyce's leadership, the Hemopurifier® was the subject of two Department of Defense (DOD) contract awards and a National Cancer Institute (NCI) contract. Mr. Joyce led the completion of approximately $100 million of equity financings on behalf of Aethlon Medical and established preclinical and clinical collaborations with more than twenty government and non-government research institutes. Based on the use of the Hemopurifier® to treat HIV and Hepatitis-C infected individuals in India, Mr. Joyce was the recipient of the “Spirit of India Award” sponsored by the Bill & Melinda Gates Foundation and awarded each year by the American India Foundation to the American business leader who has demonstrated a commitment to accelerate social and economic change in India. Mr. Joyce testified before Congress and lobbied Capitol Hill to promote the Hemopurifier® as a broad-spectrum countermeasure against bioterror and pandemic threats, which contributed to expanding the government-wide definition of treatment countermeasure to be inclusive of medical devices under U.S. law.

Anton Gopka is a Managing Member at ATEM Capital with a primary focus on private investments. Before ATEM, Anton was managing a biotech venture capital fund — a US$760 million strategic partnership between Domain Associates and a sovereign wealth fund. Notable exits include a $1.7 billion sales of Tobira Therapeutics at an unprecedented premium to its current market cap (up to 19x) and IPO of Atea Pharmaceuticals in 2020 at 30x valuation to the Series A investment back in 2014. Before that, Anton held senior positions in M&A advisory at Barclays Capital, Sistema JSFC (LSE: SSA), and Dresdner Kleinwort. Previous board memberships include Marinus Pharmaceuticals (NASDAQ: MRNS), Regado Biosciences which merged into Tobira Therapeutics (NASDAQ: TBRA), and Miramar Labs (observer). Anton received a master's degree in international economics from the Moscow State University for International Affairs (MGIMO-University), an advanced corporate finance course diploma from INSEAD, and a Board Leadership certificate from Harvard Business School. He is a member of the US National Association of Corporate Directors (NACD) and a member of the Review Committee of the National Cancer Institute (NCI). Anton enjoys life, passionate about classical music & contemporary art. FIND ANTON ON SOCIAL MEDIA LinkedIn | Facebook | Twitter ================================ SUPPORT & CONNECT: Support on Patreon: https://www.patreon.com/denofrich Twitter: https://twitter.com/denofrich Facebook: https://www.facebook.com/denofrich YouTube: https://www.youtube.com/denofrich Instagram: https://www.instagram.com/den_of_rich/ Hashtag: #denofrich © Copyright 2022 Den of Rich. All rights reserved.

Anton Gopka is a Managing Member at ATEM Capital with a primary focus on private investments. Before ATEM, Anton was managing a biotech venture capital fund — a US$760 million strategic partnership between Domain Associates and a sovereign wealth fund. Notable exits include $1.7 billion sale of Tobira Therapeutics at an unprecedented premium to its current market cap (up to 19x) and IPO of Atea Pharmaceuticals in 2020 at 30x valuation to the Series A investment back in 2014.Before that, Anton held senior positions in M&A advisory at Barclays Capital, Sistema JSFC (LSE: SSA), and Dresdner Kleinwort. Previous board memberships include Marinus Pharmaceuticals (NASDAQ: MRNS), Regado Biosciences which merged into Tobira Therapeutics (NASDAQ: TBRA), and Miramar Labs (observer). Anton received a master's degree in international economics from the Moscow State University for International Affairs (MGIMO-University), an advanced corporate finance course diploma from INSEAD, and a Board Leadership certificate from Harvard Business School.He is a member of the US National Association of Corporate Directors (NACD) and a member of the Review Committee of the National Cancer Institute (NCI). Anton enjoys life, passionate for classical music & contemporary art.FIND ANTON ON SOCIAL MEDIALinkedIn | Facebook | TwitterVisit the podcast page for additional content https://www.uhnwidata.com/podcast

Dr Mark Messina is the President of Nutrition Matters Inc, an adjunct associate professor at Loma Linda University and the Executive Director of the Soy Nutrition Institute. Mark is a former programme director with the National Cancer Institute (NCI) in the United States, and while at the NCI he initiated a multi-million dollar research programme on the anticancer effects of soy.Mark has spent the last 30 years researching the health effects of soy foods and is recognised internationally as a soy expert! Here he helps us sort fact from fiction by taking us on a deep dive into the science behind the safety, potential benefits and commonly touted concerns and misconceptions regarding soy food and human health.In this episode we discuss:• Mark's background and how he came to specialise in soy nutrition research• The history behind the soy food controversy• Whether soy isoflavones are endocrine disruptors• Soy foods and women's health; breast cancer, menopause, puberty, osteoporosis• Soy foods and men's health; isoflavones, testosterone levels, muscle protein synthesis• Soy and fertility• Heart health and soy intake• Whether the fat content of soy is a concern• Soy intake and thyroid function• Absorption of nutrients from soy foodsTo learn more about the health effects of soy, visit The Soyfoods Council and Soy Connection websites.In addition, here are some of the studies mentioned in this episode:• No Difference Between the Effects of Supplementing With Soy Protein Versus Animal Protein on Gains in Muscle Mass and Strength in Response to Resistance Exercise• Neither soy nor isoflavone intake affects male reproductive hormones: An expanded and updated meta-analysis of clinical studies• Soybean oil lowers circulating cholesterol levels and coronary heart disease risk, and has no effect on markers of inflammation and oxidation• Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: a technical review of the observational and clinical dataMake sure you subscribe to this podcast, leave us a review and share this episode with your friends and family.Please support our work and enable us to deliver more content by buying us a coffee.

With pre-print services, data sharing, open access, and the internet rapidly changing the journal publication landscape, Toxicological Sciences Editor-in-Chief Jeffrey M. Peters provides co-hosts Anne Chappelle and David Faulkner with perspective on how journals are adapting to the times. Dr. Peters also details how new training and guidance programs at ToxSci are aiming to enhance submissions and peer reviews. About the GuestJeffrey M. Peters, PhD, is a Distinguished Professor of molecular toxicology and carcinogenesis in the College of Agricultural Sciences and the Huck Institutes of the Life Sciences at the Pennsylvania State University (Penn State). He also serves as Deputy Director of the Penn State Cancer Institute, where his role is to catalyze collaborations among cancer researchers across Penn State's colleges and campuses.Dr. Peters has served on many editorial boards, including that of the Journal of Biological Chemistry, and he is the Editor-in-Chief of Toxicological Sciences, the official journal of the Society of Toxicology (SOT).Dr. Peters joined Penn State in 2000 after completing a postdoctoral fellowship at the National Cancer Institute (NCI) in Bethesda, Maryland. He holds a bachelor's degree in dietetics and a doctorate in nutrition science, both from the University of California Davis. Dr. Peters also completed postdoctoral fellowships in the Department of Cell Biology and Human Anatomy and the Institute of Toxicology and Environmental Health at UC-Davis.Dr. Peters holds long-standing NCI funding for his research program related to cancer and lipid metabolism. His laboratory studies the role of the peroxisome proliferator-activated receptors (PPARs) in the regulation of homeostasis, toxicology, and carcinogenesis. PPARs are members of the nuclear receptor superfamily and are critical modulators of environmental and dietary stimuli. The lab is particularly interested in delineating how natural compounds found in dietary constituents can activate PPARs, with the goal of identifying new molecules/proteins that can be targeted with existing approaches to improve the efficacy of chemoprevention and chemotherapy. These studies will likely lead to the identification of specific macronutrients that will effectively activate PPARs so that dietary formulations of agricultural products can be developed that will improve human and animal health and prevent serious diseases.Dr. Peters also is the Associate Director of the Center for Molecular Toxicology and Carcinogenesis at Penn State and was previously the co-leader of the Cancer Institute's Mechanisms of Carcinogenesis research program. DisclaimerThe viewpoints and information presented in Adverse Reactions represent those of the participating individuals. Although the Society of Toxicology holds the copyright to the production, it does not vet or review the information presented, nor does presenting and distributing the Adverse Reactions podcast represent any proposal or endorsement of any position by the Society.

Fully and Dave talk national synthetic data repositories and what we've learned after collecting and analyzing a year's worth of Covid-19 data. Dr. Payne is the Janet and Bernard Becker Professor and Founding Director of the Institute for Informatics at Washington University in St. Louis. He is also the Associate Dean for the Office of Health Information and Data Science and the Chief Data Scientist for Washington University. He holds appointments as a Professor of General Medical Sciences and Computer Science and Engineering in the Schools of Medicine and Engineering and Applied Sciences, respectively. In this capacity, he is responsible for the creation and oversight of comprehensive biomedical informatics and data science research, training, and support programs aligned with the health and life science enterprise spanning Washington University, BJC Healthcare, and a variety of regional partners. Further, he serves as the director of the Biomedical Informatics components/programs that exist under the auspices of both the CTSA-funded Institute for Clinical and Translational Science (ICTS) and the NCI-funded Siteman Cancer Center at Washington University. He earned both masters and doctoral degrees in Biomedical Informatics at the Columbia University College of Physicians and Surgeons. He is an elected fellow of the American College of Medical Informatics (ACMI), the American Medical Informatics Association (AMIA), and the American Institute for Medical and Biological Engineering (AIMBE), and he also holds leadership appointments on numerous national steering, editorial, and advisory committees, including efforts associated with AMIA, Association for Computing Machinery (ACM), National Cancer Institute (NCI), National Library of Medicine (NLM), and the National Center for Advancing Translational Science (NCATS). His research portfolio broadly focuses upon the areas of translational bioinformatics (TBI) and clinical research informatics (CRI) and includes projects focusing on: 1) knowledge-based approaches to high-throughput hypothesis discovery and data-driven decision making; 2) distributed data management and analysis in support of clinical and translational research; and 3) human-factors and workflow analysis.

As we approach the end of 2020, according to the U.S. National Cancer Institute (NCI), we have had approximately 1,806,590 new cases of cancer diagnosed in the United States, with 606,520 deaths. Cancer continues to be the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million. Dr. Azra Raza, MD, is the Chan Soon-Shiong Professor of Medicine, in the Department of Medicine, Division of Hematology / Oncology, and Director of the Myelodysplastic Syndrome (MDS) Center, at the Columbia University Medical Center. Previously, Dr. Raza was the Chief of Hematology-Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts. Dr. Raza is an international authority on pre-leukemia / MDS, and acute leukemia, and is both a physician and scientist who divides her time equally between caring for patients and supervising a state-of-the-art basic research lab which is well-funded by multiple large grants. Dr. Raza started collecting blood and marrow samples on her patients in 1984 and now her Tissue Bank, the largest and oldest in the country with over 60,000 samples, is considered a unique national treasure. Dr. Raza has published her original clinical and basic research comprising over 300 peer-reviewed manuscripts in high profile journals like Nature, New England Journal of Medicine, Cell, Molecular Cell, Cancer Research, Blood, Leukemia. She has published over 1,000 abstracts, dozens of book chapters and edited a book devoted to MDS, entitled "Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia: Directions for the New Millennium". Dr. Raza is the recipient of numerous awards including The Hope Award in Cancer Research 2012 (shared with the Nobel Laureate Dr. Elizabeth Blackburn). She was named as one of the 100 Women Who Matter by Newsweek Pakistan. Dr. Raza is a member of the Founder Group designing Breakthrough Developments in Science and Technology with President Bill Clinton, and was involved with Vice President Joe Biden to discuss the Cancer Moonshot initiative. Dr. Raza is the author of the recently published book "The First Cell: And the Human Costs of Pursuing Cancer to the Last". In addition to her scientific accomplishments, Dr. Raza is a dedicated reader of Urdu literature, and co-authored a book on the poems of the 19th century Indian poet Ghalib, entitled "Ghalib: Epistemologies of Elegance". 

In Episode 1, AACI President Dr. Karen E. Knudsen interviews Dr. Norman E. Sharpless, director of the National Cancer Institute (NCI). They discuss the role of the NCI and cancer centers in understanding and addressing cancer disparities, recruiting a diverse oncology workforce, the “twin pandemics” of COVID-19 and structural racism, and the 50th anniversary of the National Cancer Act. Episode Transcript Episode Links: AACI: https://aaci-cancer.org National Cancer Institute: https://cancer.gov National Cancer Act 50th Anniversary Commemoration: https://www.cancer.gov/news-events/nca50

S Pavlom Čekanom o diagnostických testoch na COVID-19, univerzálnom lieku na rakovinu a o výzvach slovenského biotechnologického sektora. ----more----Pavol Čekan získal doktorát v chémii na University of Iceland v roku 2009. Ako postdoktorand na Rockefellerovej univerzite Pavol vyvinul inovatívne metódy skúmania nukleových kyselín. Je expertom na syntézu  modifikovaných oligonukleotidov  a spektroskopickú analýzu štruktúry a funkcie nukleových kyselín. Predtým ako založil spoločnosť Multiplex DX, 4 roky pracoval v špičkovej inštitúcii venujúcej sa výskumu rakoviny - National Cancer Institute (NCI).  Pavol je autorom viac ako 35 vedeckých publikácií, vlastníkom troch patentov a je členom Vedeckého poradného zboru Ministerstva zdravotníctva Slovenskej Republiky. Je tiež členom exkluzívnej siete výkonných riaditeľov spoločností s vysokým rastovým potenciálom nazývanej Mindshare a získal niekoľko prestížnych ocenení za úspechy v oblasti biznisu a vedy.***Dobré veci potrebujú svoj čas. Staň sa patrónom Tvojho obľúbeného podcastu cez Patreon ❤️ (https://bit.ly/PatreonPD) alebo nás podpor jednorazovo či trvalým príkazom (https://bit.ly/CHCEMpodporit). Ďakujeme! 

Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for Glioblastoma (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC). VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.

In today’s episode, I am thrilled to welcome my long-time friend Roger Holzberg to the show. Roger is one of the most innovative and creative people I have had the pleasure to work with and one of the most accomplished storytellers I know. We met while both working at Disney, where Roger spent 12 years as an award-winning Creative Director / Vice President of Walt Disney Imagineering. Since then, Roger has gone on to do some truly incredible and impactful work. He is the co-founder of Reimagine Well, a company that designs and builds “immersive healing experiences” for hospitals and treatment centers. As a professor at California Institute of the Arts, Roger created the experience design in healthcare curriculum. He also served as the first consulting Creative Director for the National Cancer Institute (NCI). Roger is a father, a 15+ year cancer survivor, and a competitive triathlete, using the sport to raise research dollars for causes he supports. During our conversation, Roger provides advice for teens (and adults) to develop their creative side and engage their imagination, including his three rules for creative problem solving. He also shares the “aha moment” he experienced as a child and how it came full circle decades later. Share this conversation with your teen. It’s sure to get their creative juices flowing!

Dr. Bohr received his M.D. in 1978, Ph.D. in 1987, and D.Sc. in 1987 from the University of Copenhagen, Denmark. After training in neurology and infectious diseases at the University Hospital in Copenhagen, Dr. Bohr did a postdoctoral fellowship with Dr. Hans Klenow at the University of Copenhagen, Denmark. He then worked with Dr. Philip Hanawalt at Stanford University as a research scholar from 1982-1986. In 1986 he was appointed to the National Cancer Institute (NCI) as an investigator, becoming a tenured Senior Investigator in 1988. Dr. Bohr developed a research section in DNA repair at the NCI. In 1992 he moved to the NIA to become Chief of the Laboratory of Molecular Genetics. His main contributions have been in the area of DNA repair. He has worked on many aspects of DNA damage and its processing in mammalian cells. He developed a widely used method for the analysis of DNA repair in individual genes and found that active genes are preferentially repaired. This observation was a major advance in the clarification of the tight interaction between DNA repair and transcription, a process termed transcription-coupled repair. In recent years numerous papers from his laboratory have focused on mechanisms of DNA damage processing, particularly on nucleotide excision repair and transcription coupling. A main interest now is to elucidate how these processes change in relation to aging.

Dr. Bohr received his M.D. in 1978, Ph.D. in 1987, and D.Sc. in 1987 from the University of Copenhagen, Denmark. After training in neurology and infectious diseases at the University Hospital in Copenhagen, Dr. Bohr did a postdoctoral fellowship with Dr. Hans Klenow at the University of Copenhagen, Denmark. He then worked with Dr. Philip Hanawalt at Stanford University as a research scholar from 1982-1986. In 1986 he was appointed to the National Cancer Institute (NCI) as an investigator, becoming a tenured Senior Investigator in 1988. Dr. Bohr developed a research section in DNA repair at the NCI. In 1992 he moved to the NIA to become Chief of the Laboratory of Molecular Genetics. His main contributions have been in the area of DNA repair. He has worked on many aspects of DNA damage and its processing in mammalian cells. He developed a widely used method for the analysis of DNA repair in individual genes and found that active genes are preferentially repaired. This observation was a major advance in the clarification of the tight interaction between DNA repair and transcription, a process termed transcription-coupled repair. In recent years numerous papers from his laboratory have focused on mechanisms of DNA damage processing, particularly on nucleotide excision repair and transcription coupling. A main interest now is to elucidate how these processes change in relation to aging.

In recent decades researchers have identified more than 200 chemical exposures that may increase the risk for breast cancer. Despite these scientific advances, the country’s primary cancer agency, the National Cancer Institute (NCI), downplays these connections. This withholding of information not only affects the ability… Read More

Norman “Ned” Sharpless, MD, director of the National Cancer Institute (NCI), joins Lisa Kennedy Sheldon, PhD, ANP-BC, AOCNP®, FAAN, ONS's clinical and scientific affairs liaison, to discuss NCI's COVID-19 coronavirus research efforts, how the agency is partnering with oncology nurses to understand the best care for patients with COVID-19 and cancer, nursing innovation during the pandemic, and the implications of delayed screening and care on future cancer incidence rates.    Music Credit: "Fireflies and Stardust" by Kevin MacLeod   Licensed under Creative Commons by Attribution 3.0  Episode Notes   Check out these resources related to today's episode:    Complete this evaluation for free nursing continuing professional development.   Oncology Nursing Podcast Episode 106: NINR Director Discusses Nursing Research Amid COVID-19   ONS Voice article: Federal Agencies Collaborate; Nurse Proposes Healthcare Bill; NCI Shifts Research to COVID-19   ONS Voice article: NCI Cancer Research Persists Despite COVID-19 Limitations    ONS Recommendations for Oncology Staff Assignments During the COVID-19 Pandemic   ONS Interim Guidelines During the COVID-19 Pandemic   Dr. Sharpless's Science Editorial on COVID-19 and Cancer  Childhood Cancer Data Initiative (CCDI)  The NCI Bottom Line Blog  NCI Community Oncology Research Program (NCORP)  NCI COVID-19 in Cancer Patients Study   NCI's COVID-19 Information for Cancer Researchers   NCI-MATCH Trial        

Matthew Stoudt is the CEO and Co-Founder of AppliedVR where he is pioneering virtual reality therapeutics (VRx), the next generation of digital therapeutics. Leveraging the unique therapeutic properties of VR, AppliedVR is on a mission to enable patients with chronic pain to improve their lives through safe, effective and self-administered VRx. AppliedVR is backed by leading institutions including the NIH via the National Institute of Drug Abuse (NIDA), the National Cancer Institute (NCI), the VA, Cedars-Sinai, Cleveland Clinic, Geisinger and over 150 other institutions.  Matthew is an accomplished entrepreneur who founded and built Outcast Media, the largest out of home digital media platform in the US, exiting to Verifone in 2014. Prior to Outcast, Matthew was an Entrepreneur-in-Residence at McDonald’s where he launched several successful businesses including a digital media platform in multiple countries. Matthew began his professional career in investment banking and private equity, having raised over $1 billion in growth capital for a variety of businesses across multiple sectors. Matthew earned his MBA at Kellogg Graduate School of Business graduating with honors and his BA from Northwestern University.  Matthew is an avid traveler with a mission to visit every country in the world...if COVID will let him. About Our Partners This episode is brought to you by Hawke Media. Hawke Media is a full-service Outsourced CMO based in Santa Monica, CA, providing guidance, planning, and execution to grow brands of all sizes, industries, and business models. Hawke Media was recognized by Inc. as the country's fastest-growing marketing consultancy and is proudly one of Glassdoor's "Best Places to Work"​, 2019 #893 on the Forbes 5000 list, UpCity Top Los Angeles Digital Marketing Agency. Hawke’s collaborative process, à la carte offering, and month-to-month fee structure give clients the flexibility they need to boost digital revenues and marketing ROI. Hawke Media The company has serviced over 1500 brands of all sizes, ranging from startups like Tamara Mellon, SiO Beauty and Bottlekeeper to household names like Red Bull, Verizon Wireless and Alibaba. Listen to our interview with Erik Huberman, Founder and CEO of Hawke Media, in episode 23 of the Just Go Grind Podcast. This episode is also brought to you by Toptal. Toptal is an exclusive network of the top freelance software developers, designers, finance experts, product managers, and project managers in the world. Top companies hire Toptal freelancers for their most important projects. Connect with Matthew Stoudt AppliedVR LinkedIn Twitter AppliedVR LinkedIn AppliedVR Instagram AppliedVR Twitter AppliedVR Facebook AppliedVR YouTube Matthew@appliedvr.io Some of the Topics Covered by Matthew Stoudt in this Episode How AppliedVR got started How Matthew's wife sitting next to the CMO of Magic Leap on an airplane led Matthew to get into the world of VR What Matthew did to get AppliedVR off the ground Why the greatest impact for VR in healthcare is getting a device into patients' homes The impact of COVID on healthcare How Matthew has gone about building his team for AppliedVR Building the experience of AppliedVR's chronic pain platform Creating a proprietary biodata platform and transferring the experience into VR Combining hardware and software to create a solution for pain management Learnings from working with 60,000 patients and sending over 1,000 devices into patients' homes How Matthew and his team have gotten AppliedVR into the hands of as many patients as possible Partnerships and how they have helped AppliedVR build a trustworthy brand Why you have to tap into the entire healthcare ecosystem if you want to create real change Meeting an unmet need for patients, providers, and payers The fundraising process for AppliedVR and how they raised $23M Why it's important to be able to tell a compelling narrative New technology and how that impacts Matthew's vision for AppliedVR Why Matthew believes AppliedVR can become the CVS of VR How Matthew's time is spent day-to-day at AppliedVR Links from the Episode Magic Leap Oculus Real change through virtual reality IASP Pico Cedars-Sinai American Chronic Pain Association Beth Darnall

Dr. Jeff Prystupa joins the program to discuss the fact that 91% of breast cancer diagnosis is not cancer. This was reported in July, 2013 by the National Cancer Institute (NCI), the Journal of the American Medical Association (JAMA), and the New York Times. Dr. Jeff explains how most of the cases that are misdiagnosed are actually calcification and not cancer, and will never become cancer. Dr. Jeff Prystupa is the Research Director for Women Against Breast Cancer and the Human Patient Association. You can see more of their work at WomenAgainstBreastCancer.com (note: there is a current issue with the site, they are working on it).  2013 New York Times Article: https://well.blogs.nytimes.com/2013/07/29/report-suggests-sweeping-changes-to-cancer-detection-and-treatment/ 2013 Publication on JAMA: https://jamanetwork.com/journals/jama/article-abstract/1722196 Please support the CSPOA, the nations Sheriffs, and our constitutional rights by donating @ SheriffFund.com – the funds will be used to educate Sheriffs on how to defend our rights including against mass vaccinations. Learn more at CSPOA.org or at SheriffFund.com Note: Use the direct link: https://constitutional-sheriffs-and-peace-officers-association.snwbll.com/giving-portal if you get a safety error – this should not be occurring, but it is to some.  Snowball fundraising application is one of the most widely used fundraising applications for charities. It should be safe.    C60Complete Black Seed Oil & Curcumin Gel Capsules - Proven 200x more effective than Vitamin C! Get the latest coupons for the best cutting edge products at https://SarahWestall.com/shopConsider supporting this channel by joining Patreon at https://Patreon.com/SarahWestall – receive exclusive interviews, eBooks, coupons, and more! Stay informed on the latest shows by signing up for my weekly newsletter @ http://SarahWestall.com Follow me on Twitter @ https://twitter.com/westall_sarahw MUSIC CREDITS: “Inspiring Epilogue” by Denis/Kotenko paid license for broad internet media use, including video and audio           See more information on great products, including the C60 BlackSeed Oil Gel Caps, Snake Oil, and much more @ http://SarahWestall.com/Shop   Dr. Jeff Prystupa Biography Dr. Jeff Prystupa is the Research Director for Women Against Breast Cancer and the Human Patient Association. He started his career as a scientist with the Sloan-Kettering Cancer Institute in New York where he gain his cell level perspective on health. He later went on to earn his Doctorate in Chiropractic care and after many years of practice became the President and Committee Chairman of the Colorado Chiropractic Association.  You can learn more about his organization and the campaign to inform women on the truth about breast cancer at WomenAgainstBreastCancer.com   https://www.bitchute.com/video/nRcEntGE9IU/  

Dr. Jeff Prystupa joins the program to discuss the fact that 91% of breast cancer diagnosis is not cancer. This was reported in July, 2013 by the National Cancer Institute (NCI), the Journal of the American Medical Association (JAMA), and the New York Times. Dr. Jeff explains how most of the cases that are misdiagnosed are actually calcification and not cancer, and will never become cancer. Dr. Jeff Prystupa is the Research Director for Women Against Breast Cancer and the Human Patient Association. You can see more of their work at WomenAgainstBreastCancer.com (note: there is a current issue with the site, they are working on it).  2013 New York Times Article: https://well.blogs.nytimes.com/2013/07/29/report-suggests-sweeping-changes-to-cancer-detection-and-treatment/ 2013 Publication on JAMA: https://jamanetwork.com/journals/jama/article-abstract/1722196 Please support the CSPOA, the nations Sheriffs, and our constitutional rights by donating @ SheriffFund.com – the funds will be used to educate Sheriffs on how to defend our rights including against mass vaccinations. Learn more at CSPOA.org or at SheriffFund.com Note: Use the direct link: https://constitutional-sheriffs-and-peace-officers-association.snwbll.com/giving-portal if you get a safety error – this should not be occurring, but it is to some.  Snowball fundraising application is one of the most widely used fundraising applications for charities. It should be safe.    C60Complete Black Seed Oil & Curcumin Gel Capsules - Proven 200x more effective than Vitamin C! Get the latest coupons for the best cutting edge products at https://SarahWestall.com/shopConsider supporting this channel by joining Patreon at https://Patreon.com/SarahWestall – receive exclusive interviews, eBooks, coupons, and more! Stay informed on the latest shows by signing up for my weekly newsletter @ http://SarahWestall.com Follow me on Twitter @ https://twitter.com/westall_sarahw MUSIC CREDITS: “Inspiring Epilogue” by Denis/Kotenko paid license for broad internet media use, including video and audio           See more information on great products, including the C60 BlackSeed Oil Gel Caps, Snake Oil, and much more @ http://SarahWestall.com/Shop   Dr. Jeff Prystupa Biography Dr. Jeff Prystupa is the Research Director for Women Against Breast Cancer and the Human Patient Association. He started his career as a scientist with the Sloan-Kettering Cancer Institute in New York where he gain his cell level perspective on health.

Dr. Jeff Prystupa joins the program to discuss the fact that 91% of breast cancer diagnosis is not cancer. This was reported in July, 2013 by the National Cancer Institute (NCI), the Journal of the American Medical Association (JAMA), and the New York Times. Dr. Jeff explains how most of the cases that are misdiagnosed are actually calcification and not cancer, and will never become cancer. Dr. Jeff Prystupa is the Research Director for Women Against Breast Cancer and the Human Patient Association. You can see more of their work at WomenAgainstBreastCancer.com (note: there is a current issue with the site, they are working on it).  2013 New York Times Article: https://well.blogs.nytimes.com/2013/07/29/report-suggests-sweeping-changes-to-cancer-detection-and-treatment/ 2013 Publication on JAMA: https://jamanetwork.com/journals/jama/article-abstract/1722196 Please support the CSPOA, the nations Sheriffs, and our constitutional rights by donating @ SheriffFund.com – the funds will be used to educate Sheriffs on how to defend our rights including against mass vaccinations. Learn more at CSPOA.org or at SheriffFund.com Note: Use the direct link: https://constitutional-sheriffs-and-peace-officers-association.snwbll.com/giving-portal if you get a safety error – this should not be occurring, but it is to some.  Snowball fundraising application is one of the most widely used fundraising applications for charities. It should be safe.    C60Complete Black Seed Oil & Curcumin Gel Capsules - Proven 200x more effective than Vitamin C! Get the latest coupons for the best cutting edge products at https://SarahWestall.com/shopConsider supporting this channel by joining Patreon at https://Patreon.com/SarahWestall – receive exclusive interviews, eBooks, coupons, and more! Stay informed on the latest shows by signing up for my weekly newsletter @ http://SarahWestall.com Follow me on Twitter @ https://twitter.com/westall_sarahw MUSIC CREDITS: “Inspiring Epilogue” by Denis/Kotenko paid license for broad internet media use, including video and audio           See more information on great products, including the C60 BlackSeed Oil Gel Caps, Snake Oil, and much more @ http://SarahWestall.com/Shop   Dr. Jeff Prystupa Biography Dr. Jeff Prystupa is the Research Director for Women Against Breast Cancer and the Human Patient Association. He started his career as a scientist with the Sloan-Kettering Cancer Institute in New York where he gain his cell level perspective on health. He later went on to earn his Doctorate in Chiropractic care and after many years of practice became the President and Committee Chairman of the Colorado Chiropractic Association.  You can learn more about his organization and the campaign to inform women on the truth about breast cancer at WomenAgainstBreastCancer.com     https://youtu.be/nRcEntGE9IU

Join our host Shannon O'Connor M.D. as she interviews Mark Roschewski, M.D. Dr. Roschewski is a clinician-scientist and the clinical director of the Lymphoid Malignancies Branch (LYMB) of the Center for Cancer Research, National Cancer Institute (NCI). Tune in as they discuss new research in cancer treatment in regards to COvid19 in cancer patients.

In addition to the shock of a cancer diagnosis and stress of treatment, cancer patients  may also be at higher risk of severe illness from COVID-19 because their cancer, or its treatment, has left them more vulnerable to complications. The National Cancer Institute (NCI) launched a long-term, nationwide study of COVID-19 in people with cancer called NCI COVID-19 in Cancer Patients Study (NCCAPS). In this podcast episode, NCCS CEO Shelley Fuld Nasso speaks with leaders of the study] about how it will help scientists answer key questions about COVID-19’s impact on cancer patients, as well as cancer’s impact on the course of COVID-19. The findings have the potential to influence the treatment of cancer patients with COVID-19 in the future.

Robert Croyle, PhD, was appointed director of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI) in July 2003. You can learn more at https://cancercontrol.cancer.gov/od/director_rc.html

Henry Ford Health System and Michigan State University have announced the two organizations have signed a letter of intent (LOI) to significantly expand their long-term partnership, a unique primary affiliation among the first of its kind for the region between a fully integrated academic health system and major state university. Committed to redesigning care around our patients and communities through education, research and clinical care, the enhanced collaboration will focus on radically improving access, affordability and outcomes, especially for our most vulnerable populations.  “We've worked on a letter of intent between Henry Ford Health System and Michigan State University to develop a deep partnership in some areas we think are incredibly important,” says MSU President Samuel L. Stanley Jr., M.D. “Those areas include education. Our health colleges are very interested in working with Henry Ford to develop an actual site where we could train students and physicians.  “It's very important from a research point of view. We believe we have a number of areas where we could collaborate on research, particularly in the biomedical area. And Henry Ford would also love access to some our social scientists and some of our public health experts who they think could be helpful to them as well.  “And in clinical care, one of the challenges we've had at Michigan State University is to find a partner interested in a deeper partnership.  “This is something we're excited about and can develop with Henry Ford. We think they're a great partner. Their outreach, particularly in southeast Michigan, is extraordinary. They were one of the leading groups taking care of patients with Covid-19. And I think this ties in very well with the work we're doing in Flint. With our greater engagement with public health throughout the state, I think this partnership gives us the opportunity to increase our clinical outreach to areas that could use our help, not just in medicine, but in public health and other areas where we can make difference.”   The non-binding LOI was signed after months of talks and has several hallmark elements including a unique primary affiliation for a shared research enterprise, expanded opportunities for health students and long-term plan to build a joint Research Institute in Detroit, MI. Combined research areas will include Health Inequities and Disparities as well as Social Determinants of Health, Primary Care, Implementation Sciences, Precision Health and Cancer.  “Healthcare is more and more holistic,” adds Stanley. “It's about prevention. It's about reducing health disparities. And with Henry Ford and MSU working together, we could really develop a partnership that could really make a difference to the state of Michigan in a number of different ways.   “It's still a letter of intent at this time as we work through details of how we would bring this partnership to together. So I don't want to over promise because we're working together to get this done. But there's great enthusiasm on both sides. Each partner brings to the table a number of great strengths, and I think we could do some wonderful things together. We just need to get it figured out.”  Another major partnership component includes a fully integrated cancer program, which will combine research and clinical applications to create a national and international destination for access to the most advanced cancer therapies and research, including a joint effort to achieve National Cancer Institute (NCI) designation.  Additionally, with both institutions sharing a long history of and commitment to medical education and training, MSU and Henry Ford will expand education opportunities for physicians, nurses and other health care professionals, focused on diversity, recruitment and retention, and revolutionized training models.  Stanley believes there will be more higher education/healthcare partnerships in the future.  “This is very important for us. We have a number of talents and so many resources that we bring to these discussions that we'll look for more partnerships if we can find them.”  The two organizations will now work toward a series of definitive agreements which they hope to finalize this fall.

Isabel served 15 years in federal service as a civil servant at the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services. During her tenure at NCI, she held various positions to include Program Director of the All-Ireland NCI Cancer Consortium. Her responsibilities included evidence-based research, collaborating with foreign governments, and managing large multi-disciplinary groups of policy-makers, advocates, and scientists towards a common goal or deliverable.Academically, her work has focused on cancer prevention and women’s health, specifically breast cancer. She has also served as a spokesperson for NIH’s tobacco control efforts and worked withDr. Elmer Huerta, the first Latino President of the American Cancer Society, to educate the Hispanic community about the health risks of smoking.Her mission now is sharing it with the world!She holds a Master of Public Health degree from the prestigious Johns Hopkins Bloomberg School of Public Health and is slightly obsessed with anything health and public health-related! Her work has been published in peer-reviewed journals (including the Lancet Oncology) in the area of cancer, prevention, health education, and public health. She and her husband also own a leadership company and have held various positions within the federal government to include U.S. Department of State. She personally enjoys mentoring all ages (especially youth), and is excited to be able to help other women now start on their own personal journey to transform their your bodies!Isabel has also been featured in local Spanish radio stations to talk about health, weight loss, and diabetes.Isabel is also an avid blogger. You can read her latest blog posts about family, health, and nutrition at http://betheultimateyou.life/blogShe also invites you to join her Facebook group - Become the Ultimate You – where she shares nuggets of wisdom around health, healthy living, weight loss, chronic disease, and nutrition.Please send me your feedback, any topics you would like me to cover, any concerns and questions at showupwithpriyanka@gmail.comYou can follow me atFacebook Page: https://www.facebook.com/Show-Up-With-Priyanka-Podcast-103190054621506Instagram: https://www.instagram.com/priyankakhandalkar/Linkedin: https://www.linkedin.com/in/priyanka-khandalkar-265bab18/

Radioactive drugs carry radioactive substances that can be engineered to specifically target and kill tumor cells inside the body. In 2018, the FDA approved a radioactive drug called Lutathera to treat tumors that affect the pancreas or gastrointestinal tract. Now, scientists at the NIH led by Dr. Frank Lin are testing whether Lutathera can also be effective against rare tumors of the adrenal glands. Dr. Lin is a clinician and researcher focused on bringing radioactive drugs — also known as radionuclides — from bench to bedside. His work could accelerate the development of new therapies for patients with rare cancers who have few or no other treatment options. Frank Lin, M.D., is a Lasker Clinical Research Scholar in the Center for Cancer Research at the NIH’s National Cancer Institute (NCI). Learn more about Dr. Lin and his research at https://irp.nih.gov/pi/frank-lin

Last week was a wonderful week with well-wishes from old and new friends for my 65th birthday. It was good to see old and new friends at a pharmacy meeting last week and then reconnect with old friends via email and Facebook, some dating back to my high school days!!I admit that a huge weight was lifted from my shoulders last week. Turning 65 means being eligible for Medicare. Although I’m still working and have health insurance, I also have a history of breast cancer, a “pre-existing condition” in insurance terms.My mother taught me to always look at a job offer in total. Was it a company I wanted to work for from an ethical standpoint? Was the offer fair for the skills I had to offer? But she also taught me that even more important than the salary, was the health insurance. My brother was disabled and my mother understood even in the 1940’s how expensive healthcare would become. I was relatively healthy until 2006 when I was diagnosed with breast cancer. I had wonderful doctors with a treatment plan involving multiple surgeries and long-term hormonal suppression therapy. I was declared “cured” in 2006 after a left mastectomy and I was lucky that it was caught early. I didn’t need any other chemotherapy or radiation but was on oral suppression therapy for six years to prevent a recurrence. Cancer put my life on pause, changing it forever.In November 2011, five years after my doctors declared me “cured”, I applied for, and was turned down for, long-term disability insurance through my employer. This was outsourced to a third-party insurance company and I was again turned down on appeal. Although I was five years cancer-free, the insurance company indicated that I had a “pre-existing” condition which did not meet their guidelines for insurance.I know first-hand what it was like in my 50’s to be turned down for insurance.I don’t think that Medicare for everyone is the answer, but my personal cancer diagnosis is a “pre-existing” condition that caused me to worry that if I ever lost my job, I would be uninsurable. But now, I’m Medicare-eligible.I work out, have no chronic medical conditions and try to eat right. I take no medications but a Vitamin D supplement every day. But it is impossible to predict what the future holds.As of Friday, I no longer need to worry about being “uninsurable”. The National Cancer Institute (NCI) estimated in 2016 that 15.5 million people have been diagnosed with cancer and are living with that diagnosis day-to-day.That is a lot of US citizens that could be “uninsurable” if insurance companies can deny insurance based upon the “pre-existing condition” of “cancer survivor”. Blessings, my friend,Agatha

Members from Team Telomere (formerly DC Outreach), a community for telomere biology disorders join me for this episode. This panel includes patient advocate Katie Stevens, Dr. Sharen Savage, and Dr. Suneet Agarwal. They provide information and support services to families worldwide who are affected by these disorders, encourage the medical community’s research in finding causes and effective treatments, and facilitate improved diagnosis by educating medical providers.Katie Stevens is the Executive Director of Team Telomere. Her oldest child, Riley, is affected by a telomere disorder. Katie’s goal is to be an advocate and resource. She is also a member of Global Genes Foundation Alliance Advisory Council and a NORD member leader.Dr. Sharon Savage is the Chief of the Clinical Genetics Branch in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI). She leads clinical, genetic, and epidemiologic studies of individuals and families at high risk of cancer. Dr. Savage’s research program in telomere molecular epidemiology incorporates population-based studies of telomere length and disease with genetic studies of telomere biology. She serves as a Medical Advisor for Team Telomere.Dr. Suneet Agarwal completed his M.D. and Ph.D. training at Harvard Medical School. He is currently an Assistant Professor in Pediatrics at Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute and Harvard Initiative in RNA Medicine, and Staff Physician in Hematopoietic Cell Transplantation at the Dana-Farber / Boston Children’s Cancer and Blood Disorders Center. Dr. Agarwal's research and clinical work is focused on the mechanisms and treatment of genetic blood disorders. He leads a multi-center bone marrow transplant clinical trial for dyskeratosis congenita, and his lab is working on new therapeutic approaches for telomere diseases. He also serves as a Medical Advisor for Team Telomere.This Episode We DiscussKatie’s Son’s Diagnostic JourneyDyskeratosis Congenita and Telomere Biology DisorderPrevalenceSymptomsAge of OnsetAssociated GenesDiagnosis ProcessTreatmentsLatest ResearchHow Team Telomere Helps Affected FamiliesBecoming a Bone Marrow Donor > BeTheMatch.orgStay tuned for the next new episode of DNA Today on November 2nd, 2018. New episodes are released on the first and third Fridays of the month. Can’t wait? There are over 90 episodes to explore in the meantime.See what else I am up to on Twitter, Instagram, Facebook and iTunes. Questions/inquiries can be sent to Kira at info@DNApodcast.com.

The big headline out of the health care M&A world today is Swiss pharmaceutical giant Roche’s $1.9 billion acquisition of Flatiron Health, the Alphabet-backed, cancer-focused digital health analytics upstart that’s attempting to use real world patient information and big data to spur better oncology R&D. Flatiron’s cancer-centric electronic health records platform is linked to some 250 community oncology practices; it has a partnership with the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to improve clinical trials by gathering data at the point of care. What’s made the company appealing to venture capital outfits, the drug industry, and the government is that Flatiron doesn’t just suck in a bunch of numbers and spit them out—its datasets are curated in an effort to separate statistical noise from actionable information. That’s hard to pull off on a mass scale. - From Fortune.com Subscribe to us on youtube: https://www.youtube.com/channel/UCe_8N --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/clinical-research-podcast/message Support this podcast: https://anchor.fm/clinical-research-podcast/support

Since 1980, rates of obesity have doubled in 2- to 5-year-olds, quadrupled in 6- to 11-year-olds, and tripled in 12- to 19-year-olds. The organization, ChildObesity180, is a leader in taking a unique approach to reverse the epidemic among children ages 5 to 12 years. They bring together the best of public health practice and business expertise to create initiatives that impact various aspects of a child’s environment. Working to reduce health disparities is their priority, and they incorporate this focus into all of their initiatives. ChildObesity180 effectively promotes achieving and maintaining a healthy weight in children throughout the nation. Dr. Hennessy works with ChildObesity180 to advance their research and evaluation activities and scholarship. Prior to joining the Friedman Faculty, Dr. Hennessy was a Senior Behavioral Scientist at the National Cancer Institute (NCI), National Institutes of Health. During her tenure, she led multiple research activities aimed to incorporate novel methodologies into behavioral research. I asked Dr. Hennessy to provide insight and possible solutions to the problem of childhood obesity that we can take on as parents, teachers, doctors, community members and anyone who cares about the future of our kids. Dr. Hennessy is delightful and joy to speak to. I hope you enjoy this conversation as much as I did. You can learn more about ChildObesity180 here. http://www.childobesity180.org Thank you for listening as always. Please share this video with anyone who cares about our kids and their future.

Deana Chiusano was 39 years old when she was diagnosed with multiple myeloma in April 2011. She sought the most effective treatment for her specific type of cancer that led her to Winship Cancer Institute of Emory University - the state of Georgia's only National Cancer Institute (NCI) designated comprehensive cancer center.A cancer discovery in Winship's multiple myeloma lab led to enrollment on a trial that has transformed Deana's battle with the disease. Deana lives in Pittsburgh but travels to Atlanta every three weeks for treatment. After years of treatments elsewhere with minimal response, Deana has seen dramatic improvement with this tailored therapy from compassionate nurses and staff.Joining the show to discuss an innovative tailored therapy for multiple myeloma from a patients perspective, is Colleen Lewis, MSN, ANP-BC, AOCNP, and Deana Chiusano.

Ethan Basch, MD talks today about a randomized clinical trial where 766 patients used a web-based system to self-report symptoms, triggering alerts to clinicians. The results were impressive. There are learnings and inspiration in this episode for anyone pursuing better patient outcomes, with special relevance for organizations rolling with a value-based care model. Dr. Ethan Basch is an oncologist and Director of Cancer Outcomes Research at the University of North Carolina.  His research group established that up to half of patients' symptom side effects go undetected during cancer treatment and clinical trials, and that patient engagement and questionnaires substantially improve detection. His team determined that integrating web-based patient-reported symptoms into oncology clinical practice improves clinical outcomes and reduces health service utilization. His team created a system for the National Cancer Institute (NCI) to collect patient-reported side effects during cancer trials called the ‘PRO-CTCAE.' Dr. Basch is also involved in efforts to bring PROs into comparative effectiveness research, routine care, and quality improvement. He is a member of the U.S. National Cancer Institute's Board of Scientific Advisors, PCORI's Methodology Committee, and is an Associate Editor at JAMA.  Dr. Basch will discuss results of a widely cited randomized controlled trial testing a “PRO intervention” in routine cancer care, that was a Plenary session at the ASCO annual cancer meeting and was published in JAMA earlier this year.  In this trial, 766 patients receiving routine outpatient chemotherapy for metastatic solid tumors were randomly assigned to self-report 12 common symptoms via the web, or to usual care. Treating physicians received symptom printouts at visits and nurses received email alerts when participants reported severe or worsening symptoms. Overall survival was tabulated based on medical records and Social Security Death Index data, estimated using the Kaplan-Meier method, and compared between arms using a log-rank test and Cox proportional hazards regression adjusting for age, sex, race, education level, and cancer type.  Cancer types included genitourinary (32% of patients), gynecologic (23%), breast (19%), and lung cancer (26%).  Survival results were assessed after a median follow up of 7 years and 517/766 (67%) of participants had died.  Median overall survival in the PRO intervention arm was 5.2 months longer than the control arm (31.2 vs. 26.0 months, p=0.03).  These results demonstrate that systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes confers overall survival benefits.  These results are being further explored in a U.S. national implementation trial. 00:00 Ethan talks his work on a self-reporting symptom system. 02:20 The results of the self-reporting system trial. 03:00 Does using a self-reporting symptom system improve Clinical Outcomes? 04:30 Analyzing the data from this self-reporting system. 09:45 The improvements in Quality of Life this self-reporting study found. 10:20 The decrease in ER visits with self-reporting symptoms. 10:45 The extension of chemotherapy treatments self-reporting patients were able to achieve. 12:50 What inspired Ethan to take this sort of a project on. 13:15 The opportunity to improve the ability to detect patient symptoms. 15:30 Refining study techniques and approaches for successful trials. 19:20 Onboarding patients for studies. 24:15 Implementing the study from the Clinician side. 26:20 The requirements needed for onboarding staff onto a successfully implemented study. 29:45 The relevance to Value-Based Reimbursement. 31:00 The tangible impacts of catching symptoms early that increased the survival benefit of patient-reporting. 34:00 EP131, relevant insight from Zach Silverzweig of Cipherhealth. 36:00 A better way to monitor how patients are doing and improve the quality of care. 37:20 You can learn more about the study in the Journal of the American Medical Association & the Journal of Clinical Oncology.

Dr Comis talks to ecancertv at ASCO 2015 about a National Cancer Institute (NCI) sponsored cancer clinical trial for under-represented populations that aims to refine the calculation of accrual targets.

Brain Cancer. Wow. BethAnn Telford, in 2004, while running the Marine Corps Marathon, she felt a “pop” in her head around mile marker nineteen and over the next couple of months started to experience problems with her balance and unclear thoughts. After several weeks of tests in the early winter of 2005, she learned she had a brain tumor and that her life would forever be changed. In April of 2005, she had her first brain surgery and had to learn to walk, talk, and move all over again. As her rehabilitation began, she was determined to run again. Six weeks later she ran her first 5K race and trained throughout the summer to run and finish the Marine Corps Marathon. Stopping at mile marker nineteen to say reflect on her journey and to silently thank her doctors, family and friends that have supported her during her struggles. Since then, BethAnn has undergone a second brain surgery, a nuerostimulator implant and bladder augmentation surgery for issues related to her brain cancer. Through it all, Beth has competed and finished Boston Marathons (six (6) times), Marine Corp Marathons (thirteen (13) times), the Lake Placid Ironman (twice (2)), the Kona Ironman World Championships (in 2012), and Crossing the Canyon (a 9 hour rim-to-rim trek of the Grand Canyon). She has currently completed an epic adventure in January 2017, the World Marathon Challenge, which consists of running 7 marathons on 7 continents in 7 days. In addition to her pushing her physical boundaries, BethAnn has dedicated herself to helping raise awareness of brain cancer and toward finding a cure. BethAnn founded Team BT as part of the Race for Hope - DC 5K Run/Walk and has helped raise more than $800,000 for brain cancer research. She has participated in countless charity and fund raising events, including rappelling down the side of a skyscraper as part of an ABC2 event to help raise awareness and funds for brain cancer research. In addition to fund raising, BethAnn has testified before an FDA committee on the benefits of advance drug therapies, advocated through lobbying Congress, and advocated as part of the National Cancer Institute (NCI) and White House briefing since the fall of 2014. She has also had two (2) NBTS grants awarded to the Cleveland Clinic and the University of Florida in her name and been awarded the Triumph of Spirit award. She has also been featured in countless articles, news stories including the front page of the Washington Post, and has been featured in a Discovery Program documentary. Get Involved http://abc2.org/ ABC2 breaks through the boundaries of academia, nonprofits, industries and other research fields to find the cure. To reach new treatments faster, we're helping our partners connect, learning from our failures and sharing one another's successes. As venture philanthropists, we “buy down the risk” for researchers to connect with the companies that can develop new patient treatments. We have to push more research through that drug development “Valley of Death” before we can start learning from results — from successes and failures. By challenging long-held attitudes about brain cancer research, we’re charting a more direct course towards the cure. Follow BethAnn Facebook: https://www.facebook.com/TeamBethAnnTelford/  ======================  Request to Join the FREE Meredith Atwood Community & Coaching https://meredith-atwood-coaching.mn.co/ ======================  Buy Meredith’s Books: The Year of No Nonsense https://amzn.to/3su5qWp Triathlon for the Every Woman: https://amzn.to/3nOkjiH =======================   Follow Meredith Atwood & The Podcast on Social: Web: http://www.swimbikemom.com Instagram: http://instagram.com/swimbikemom   =======================  Want to Connect?  Email: same24hourspodcast@gmail.com =======================  Credits: Host & Production: Meredith Atwood Intro: Carl Stover Music Copyright 2017-2020, 2021 All Rights Reserved, Meredith Atwood, LLC

Religious and spiritual values have been reported by many patients as important cancer coping tools. According to the National Cancer Institute (NCI) “the terms spirituality and religion are often used in place of each other, but for many people they have different meanings.”Join Fight CRC's Sharyn Worrall, and Chaplain Michael Eselun, BCC from the Simms/Mann UCLA Center for Integrative Oncology as they explore the role of spirituality and cancer. 

Dr Park presents at ASCO 2016, the results of a National Cancer Institute (NCI) funded phase III trial performed by the Children’s Oncology Group which found that adding a second autologous stem-cell transplant (ASCT, a transplant that uses the patient’s own stem cells) to standard therapy improves outcomes for these patients.

Host Dawn Davenport, Executive Director of Creating a Family, the national infertility & adoption education and support nonprofit, interviews Dr. Louise Brinton, Senior Scientific Advisor for the Division of Cancer Epidemiology and Genetics of the National Cancer Institute (NCI).  During her 40 year career with the NCI, she has focused her research on a wide variety of exposures related to cancer risks among women, including reproductive factors and fertility drugs; Humberto “Bert” Scoccia, MD, Professor and Director of the Division of Reproductive Endocrinology and Infertility in the Department of Obstetrics and Gynecology at the University of Illinois College of Medicine in Chicago; and Alice Crisci, breast cancer survivor, activist and author. Creating a Family has many free resources related to this topic on our website at www.CreatingaFamily.org. Please leave us a review on iTunes. Thanks. Click to Tweet: http://ctt.ec/b8ej6 Facebook Share: https://www.facebook.com/sharer/sharer.php?u=https%3A//creatingafamily.org/infertility-category/infertility-treatment-breastovarian-cancer/ Show Highlights: https://creatingafamily.org/infertility-category/infertility-treatment-breastovarian-cancer/ Support the show (https://creatingafamily.org/donation/)

July 07, 2011 "This Week in Pediatric Oncology" podcast host Dr. Tim Cripe interviewed Dr. Robert Seeger from CHLA (Children's Hospital of Los Angeles) about his contributions to improvements in treating neuroblastoma as well as his vision for future advances. Dr. Seeger's career has been remarkable in that he began with an interest in immunotherapy and neuroblastoma as an intriguing model for this approach, and has consequently been involved in every major advance in treating neuroblastoma, including the pivotal 1984 discovery of the first-everamplification of an oncogene for any cancer – MYCN and the 1985 demonstration that MCYN could be used to predict survival. Authoring over 180 publications, Dr. Seeger has made a significant contribution to every step toward developing better therapies for neuroblastoma, including induction therapy, myeloablative therapy, immunotherapy with anti-GD2 antibody and cytokines, maintenance therapy with retinoids, and most recently, work in tumor microenvironment and developing reproducible biomarkers for detecting minimal residual disease. At the beginning of Dr. Seeger’s career, survival for high-risk neuroblastoma was abysmal at about 5%, and now survival is about 45%. Dr Seeger has been a leader in the NANT consortium (New Approaches to Neuroblastoma Therapy) and involved in planning the early phase clinical trials conducted by this 15-member consortium. When questioned about current challenges in his research, Dr. Seeger mentioned the increased regulatory burdens associated with developing new treatments, and also discussed the need for preclinical (mouse) models that are predictive and well-validated. Dr Seeger believes that improvements can be made in functional imaging, including developing pharmacodynamic markers to detect impact of therapy on tumor. Dr. Seeger is Professor and Division Head for Basic and Translational Research at Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles/USC School of Medicine in Los Angeles, CA. His research interests are neuroblastoma risk assessment by gene expression profiling at diagnosis; evaluating response to treatment by quantifying rare neuroblastoma cells in blood and bone marrow; immunotherapy of neuroblastoma (natural killer cells, anti-tumor antibodies, tumor associated macrophages). Dr. Seeger is a reviewer for several high-impact oncology journals, and is a member of the COG NB steering committee. He earned his MD at Oregon Health Sciences University School of Medicine in Portland and completed pediatric internship and residency at the University of Minnesota Medical School in Minneapolis. Additionally, Dr. Seeger obtained research fellowship training at the National Cancer Institute (NCI) and the ICRF Tumor Immunology Unit at University College London, UK. Please email questions or comments to twipo@solvingkidscancer.org

On the Wednesday, May 15th 2013 broadcast at 10AM Pacific/1PM Eastern we chat with the principal organizers of the collaborative Office of the National Coordinator (ONC) and National Cancer Institute (NCI) application developer challenge. Assisted by Health 2.0 Challenge Program and powered by the Medstartr crowdfunding and challenge optimization platform, Crowds Care for Cancer is further detailed in:'New Developer Contest – Create a Cancer Survivor Tool' and via 'Crowds Care for Cancer: Supporting Survivors'. Joining us from the Office of the National Coordinator for HealthIT (ONC) is Adam Wong, a Management and Program Analyst and Project Officer for the Inventing Innovation Program, and Abdul Shaikh, PhD, Program Director, Health Communications and Informatics, National Cancer Institute (NCI). The challenge is the latest in an ongoing series of public/private collaboration and partnerships designed to stimulate innovation in the healthcare and healthtech space while energizing a full court press towards both the meaningful use of electronic connectivity as well as the broader cast 'triple aim'. Join my HIBC.tv co-founder colleagues Alex Fair, Medstartr and Pat Salber HealthTech Hatch for an informative chat with the principal program drivers the 'Crowds Care for Cancer Supporting Survivors' Challenge.

The National Cancer Institute (NCI) currently supports 61 designated Cancer Centers in the U.S.A. There are 22 Basic or Clinical Cancer Centers and 39 Comprehensive Cancer Centers. (September 16, 2007)

Dr. Cheryl Willman was named executive director of Mayo Clinic Cancer Programs, and director of the Mayo Clinic Cancer Center in May. In this role, Dr. Willman is leading the expansion and strategic development of Mayo Clinic Cancer Center locations in Arizona, Florida and Minnesota, as well as newly developing Mayo Clinic global cancer programs in London and Abu Dhabi, United Arab Emirates.Mayo Clinic Cancer Center is designated by the National Cancer Institute (NCI) as a comprehensive cancer center. At comprehensive cancer centers, staff coordinate innovative cancer care delivery for patients; conduct team-based cancer research to develop better means to prevent, detect and treat cancer; involve communities and patients in research; and train the next generation of cancer health professionals. Mayo Clinic Cancer Center offers its patients access to hundreds of clinical trials in all phases that test new and improved cancer treatments. "We have a menu of over 300 cancer clinical trials every year that are testing new drugs and bringing treatments to patients," says Dr. Willman. "Cancer clinical trials are essential to advancing our knowledge in cancer care."Work is underway at Mayo Clinic Cancer Center to grow the Cancer Care at Home program and engage local communities, which can help address disparities in health care. Other initiatives include making advances in radiation therapy techniques and using genomics to develop individualized care for patients.Mayo Clinic Cancer Center also is expanding the use of patient navigators, allowing cancer patients to have one point of contact to help them navigate the complexities of cancer care that often involves many specialists. "For a breast cancer patient, for example, that would include breast cancer surgeons, medical oncologists who give chemotherapy, radiation oncologists who give radiation, but also physical medicine and rehabilitation, nutrition, psychosocial support, and access to clinical trials," says Dr. Willman. "A patient navigator becomes the primary contact person for a patient we're caring for and truly navigates them through all of their providers."On the Mayo Clinic Q&A podcast, Dr. Willman discusses the innovations taking place at Mayo Clinic to improve cancer care for patients. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy